-
1
-
-
84856808226
-
World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA
-
22327426
-
Dhimolea E, Reichert JM. World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA. MAbs 2012; 4:4-13; PMID:22327426; http://dx.doi.org/10.4161/mabs.4.1.18821
-
(2012)
MAbs
, vol.4
, pp. 4-13
-
-
Dhimolea, E.1
Reichert, J.M.2
-
2
-
-
84922391726
-
Bispecific antibodies rise again
-
25359367
-
Garber K. Bispecific antibodies rise again. Nat Rev Drug Discov 2014; 13:799-801; PMID:25359367; http://dx.doi.org/10.1038/nrd4478
-
(2014)
Nat Rev Drug Discov
, vol.13
, pp. 799-801
-
-
Garber, K.1
-
3
-
-
84924425633
-
Amgen's bispecific antibody puffs across finish line
-
25748895
-
Sheridan C. Amgen's bispecific antibody puffs across finish line. Nat Biotechnol 2015; 33:219-21; PMID:25748895; http://dx.doi.org/10.1038/nbt0315-219
-
(2015)
Nat Biotechnol
, vol.33
, pp. 219-221
-
-
Sheridan, C.1
-
4
-
-
84862251353
-
Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on
-
22896757
-
Riethmüller G. Symmetry breaking:bispecific antibodies, the beginnings, and 50 years on. Cancer Immunity 2012; 12:12; PMID:22896757
-
(2012)
Cancer Immunity
, vol.12
, pp. 12
-
-
Riethmüller, G.1
-
5
-
-
0001303221
-
Recombination of a mixture of univalent antibody fragments of different specificity
-
13729244
-
Nisonoff A, Rivers MM. Recombination of a mixture of univalent antibody fragments of different specificity. Arch Biochem Biophys 1961; 93:460-2; PMID:13729244
-
(1961)
Arch Biochem Biophys
, vol.93
, pp. 460-462
-
-
Nisonoff, A.1
Rivers, M.M.2
-
6
-
-
0016756272
-
Continuous cultures of fused cells secreting antibody of predefined specificity
-
1172191
-
Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-7; PMID:1172191
-
(1975)
Nature
, vol.256
, pp. 495-497
-
-
Köhler, G.1
Milstein, C.2
-
7
-
-
0021860882
-
Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments
-
3925553
-
Brennan M, Davison PF, Paulus H. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science 1985; 229:81-3; PMID:3925553
-
(1985)
Science
, vol.229
, pp. 81-83
-
-
Brennan, M.1
Davison, P.F.2
Paulus, H.3
-
8
-
-
0020518331
-
Hybrid hyridomas and their use in immunohistochemistry
-
6137772
-
Milstein C, Cuello AC. Hybrid hyridomas and their use in immunohistochemistry. Nature 1983; 305:537-40; PMID:6137772
-
(1983)
Nature
, vol.305
, pp. 537-540
-
-
Milstein, C.1
Cuello, A.C.2
-
9
-
-
0035251453
-
Bispecific human IgG by design
-
11223065
-
Carter P. Bispecific human IgG by design. J Immunol Methods 2001; 248:7-15; PMID:11223065
-
(2001)
J Immunol Methods
, vol.248
, pp. 7-15
-
-
Carter, P.1
-
10
-
-
11844273237
-
Recombinant bispecific antibodies for cancer therapy
-
15659107
-
Kontermann RE. Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol Sin 2005; 26:1-9; PMID:15659107; http://dx.doi.org/10.1111/j.1745-7254.2005.00008.x
-
(2005)
Acta Pharmacol Sin
, vol.26
, pp. 1-9
-
-
Kontermann, R.E.1
-
12
-
-
84959513494
-
Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection
-
26963133
-
Zhukovsky EA, Morse RJ, Maus MV. Bispecific antibodies and CARs:generalized immunotherapeutics harnessing T cell redirection. Curr Opin Immunol 2016; 40:24-35; PMID:26963133; http://dx.doi.org/10.1016/j.coi.2016.02.006
-
(2016)
Curr Opin Immunol
, vol.40
, pp. 24-35
-
-
Zhukovsky, E.A.1
Morse, R.J.2
Maus, M.V.3
-
15
-
-
84912138759
-
Bispecific antibody platforms for cancer immunotherapy
-
25195094
-
Lameris R, de Bruin RC, Schneiders FL, van Bergen en Henegouwen PM, Verheul HM, de Gruijl TD, van der Vliet HJ. Bispecific antibody platforms for cancer immunotherapy. Crit Rev Oncol hematol 2014:92:153-65,DOI:10.1016/j.critrevonc.2014.08.003; PMID:25195094
-
(2014)
Crit Rev Oncol hematol
, vol.92
, pp. 153-165
-
-
Lameris, R.1
de Bruin, R.C.2
Schneiders, F.L.3
van Bergen en Henegouwen, P.M.4
Verheul, H.M.5
de Gruijl, T.D.6
van der Vliet, H.J.7
-
16
-
-
82755197856
-
Strategies for extended serum half-life of protein therapeutics
-
21862310
-
Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 2011; 22:868-76; PMID:21862310; http://dx.doi.org/10.1016/j.copbio.2011.06.012
-
(2011)
Curr Opin Biotechnol
, vol.22
, pp. 868-876
-
-
Kontermann, R.E.1
-
17
-
-
84858257263
-
Dual targeting strategies with bispecific antibodies
-
Kontermann RE. Dual targeting strategies with bispecific antibodies. mAbs 2012; 4:182-97
-
(2012)
mAbs
, vol.4
, pp. 182-197
-
-
Kontermann, R.E.1
-
18
-
-
84891804917
-
Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle
-
24411731
-
Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, Maier P, Rueger P, Stracke JO, Lau W, Tissot AC, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 2014; 81:49-60; PMID:24411731; http://dx.doi.org/10.1016/j.neuron.2013.10.061
-
(2014)
Neuron
, vol.81
, pp. 49-60
-
-
Niewoehner, J.1
Bohrmann, B.2
Collin, L.3
Urich, E.4
Sade, H.5
Maier, P.6
Rueger, P.7
Stracke, J.O.8
Lau, W.9
Tissot, A.C.10
-
19
-
-
84994431107
-
Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain penetrating bi-specific antibodies
-
27572805
-
Pardridge WM. Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain penetrating bi-specific antibodies. Expert Opin Biol Ther 2016; 7:1-14; PMID:27572805; http://dx.doi.org/10.1080/14712598.2016.1230195
-
(2016)
Expert Opin Biol Ther
, vol.7
, pp. 1-14
-
-
Pardridge, W.M.1
-
20
-
-
1942502345
-
A revival of bispecific antibodies
-
15109810
-
Kufer P, Lutterbüse R, Baeuerle PA. A revival of bispecific antibodies. Trends Biotechnol 2004; 22:238-44; PMID:15109810; http://dx.doi.org/10.1016/j.tibtech.2004.03.006
-
(2004)
Trends Biotechnol
, vol.22
, pp. 238-244
-
-
Kufer, P.1
Lutterbüse, R.2
Baeuerle, P.A.3
-
21
-
-
77951523463
-
Bispecific antibodies for cancer therapy: the light at the end of the tunnel?
-
20073127
-
Chames P, Baty D. Bispecific antibodies for cancer therapy:the light at the end of the tunnel? MAbs 2009; 1:539-47; PMID:20073127
-
(2009)
MAbs
, vol.1
, pp. 539-547
-
-
Chames, P.1
Baty, D.2
-
22
-
-
77749239974
-
Bispecific antibodies for cancer immunotherapy: current perspectives
-
20556545
-
Müller D, Kontermann RE. Bispecific antibodies for cancer immunotherapy:current perspectives. BioDrugs 2010; 24:89-98; PMID:20556545; http://dx.doi.org/10.1007/s12033-010-9298-x
-
(2010)
BioDrugs
, vol.24
, pp. 89-98
-
-
Müller, D.1
Kontermann, R.E.2
-
23
-
-
84886099419
-
A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications
-
24094861
-
Byrne H, Conroy PJ, Whisstock JC, O'Kennedy RJ. A tale of two specificities:bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol 2013; 31:621-32; PMID:24094861; http://dx.doi.org/10.1016/j.tibtech.2013.08.007
-
(2013)
Trends Biotechnol
, vol.31
, pp. 621-632
-
-
Byrne, H.1
Conroy, P.J.2
Whisstock, J.C.3
O'Kennedy, R.J.4
-
24
-
-
84936847342
-
Bispecific antibodies
-
25728220
-
Kontermann R, Brinkmann U. Bispecific antibodies. Drug Discov Today 2015; 20:838-47; PMID:25728220; http://dx.doi.org/10.1016/j.drudis.2015.02.008
-
(2015)
Drug Discov Today
, vol.20
, pp. 838-847
-
-
Kontermann, R.1
Brinkmann, U.2
-
25
-
-
84909639757
-
Tumor-antigen-binding bispecific antibodies for cancer treatment
-
25440609
-
Weidle UH, Kontermann RE, Brinkmann U. Tumor-antigen-binding bispecific antibodies for cancer treatment. Semin Oncol 2014; 41:653-60; PMID:25440609; http://dx.doi.org/10.1053/j.seminoncol.2014.08.004
-
(2014)
Semin Oncol
, vol.41
, pp. 653-660
-
-
Weidle, U.H.1
Kontermann, R.E.2
Brinkmann, U.3
-
26
-
-
84907982724
-
Engineering and pharmacology of blood-brain barrier-permeable bispecific antibodies
-
25307221
-
Stanimirovic D, Kemmerich K, Haqqani AS, Farrington GK. Engineering and pharmacology of blood-brain barrier-permeable bispecific antibodies. Adv Pharmacol 2014; 71:301-35; PMID:25307221; http://dx.doi.org/10.1016/bs.apha.2014.06.005
-
(2014)
Adv Pharmacol
, vol.71
, pp. 301-335
-
-
Stanimirovic, D.1
Kemmerich, K.2
Haqqani, A.S.3
Farrington, G.K.4
-
27
-
-
84926348347
-
Alternative molecular formats and therapeutic applications for bispecific antibodies
-
25637431
-
Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol 2015; 67:95-106; PMID:25637431; http://dx.doi.org/10.1016/j.molimm.2015.01.003
-
(2015)
Mol Immunol
, vol.67
, pp. 95-106
-
-
Spiess, C.1
Zhai, Q.2
Carter, P.J.3
-
28
-
-
84989862751
-
Bispecific antibody mimicking factor VIII
-
27207420
-
Nogami K. Bispecific antibody mimicking factor VIII. Thromb Res 2016; 141 Suppl 2:S34-35; PMID:27207420; http://dx.doi.org/10.1016/S0049-3848(16)30361-9
-
(2016)
Thromb Res
, vol.141
, pp. S34-S35
-
-
Nogami, K.1
-
29
-
-
0032212020
-
Bispecific antibodies as novel bioconjugates
-
9815155
-
Cao Y, Suresh MR. Bispecific antibodies as novel bioconjugates. Bioconjugat Chem 1998; 9:635-44; PMID:9815155; http://dx.doi.org/10.1021/bc980044l
-
(1998)
Bioconjugat Chem
, vol.9
, pp. 635-644
-
-
Cao, Y.1
Suresh, M.R.2
-
30
-
-
77953188563
-
Cancer therapy with bispecific antibodies: clinical experience
-
20521223
-
Thakur A, Lum LG. Cancer therapy with bispecific antibodies:clinical experience. Curr Opin Mol Ther 2010; 12:340-9; PMID:20521223
-
(2010)
Curr Opin Mol Ther
, vol.12
, pp. 340-349
-
-
Thakur, A.1
Lum, L.G.2
-
31
-
-
84858249264
-
Generation of bispecific antibodies by chemical conjugation
-
Kontermann R.E., (ed), Springer-Verlag, Berlin Heidelberg:
-
Ellerman D, Scheer JM. Generation of bispecific antibodies by chemical conjugation. In. Bispecific antibodies (ed Kontermann RE,), Springer-Verlag Berlin Heidelberg, 2011; 47-63; http://dx.doi.org/10.1007/978-3-642-20910-9_3
-
(2011)
Bispecific antibodies
, pp. 47-63
-
-
Ellerman, D.1
Scheer, J.M.2
-
32
-
-
78651091039
-
Chemical generation of bispecific antibodies
-
21149738
-
Doppalapudi VR, Huang J, Liu D, Jin P, Liu B, Li L, Desharnais J, Hagen C, Levin NJ, Shields MJ, et al. Chemical generation of bispecific antibodies. Proc Natl Acad Sci USA 2010; 107:22611-6; PMID:21149738; http://dx.doi.org/10.1073/pnas.1016478108
-
(2010)
Proc Natl Acad Sci USA
, vol.107
, pp. 22611-22616
-
-
Doppalapudi, V.R.1
Huang, J.2
Liu, D.3
Jin, P.4
Liu, B.5
Li, L.6
Desharnais, J.7
Hagen, C.8
Levin, N.J.9
Shields, M.J.10
-
33
-
-
84964461974
-
Heavy and light chain pairing of bivalent quadroma and knobs-into-holes antibodies analyzed by UHR-ESI-QTOF mass spectrometry
-
26496506
-
Schaefer W, Völger HR, Lorenz S, Imhof-Jung S, Regula JT, Klein C, Mølhøj M. Heavy and light chain pairing of bivalent quadroma and knobs-into-holes antibodies analyzed by UHR-ESI-QTOF mass spectrometry. MAbs 2016; 8:49-55; PMID:26496506; http://dx.doi.org/10.1080/19420862.2015.1111498
-
(2016)
MAbs
, vol.8
, pp. 49-55
-
-
Schaefer, W.1
Völger, H.R.2
Lorenz, S.3
Imhof-Jung, S.4
Regula, J.T.5
Klein, C.6
Mølhøj, M.7
-
34
-
-
84859715471
-
ScFv antibody: principles and clinical application
-
22474489
-
Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NB, Hamid M. ScFv antibody:principles and clinical application. Clin Dev. Immun 2012; 2012:980250; PMID:22474489; http://dx.doi.org/10.1155/2012/980250
-
(2012)
Clin Dev. Immun
, vol.2012
, pp. 980250
-
-
Ahmad, Z.A.1
Yeap, S.K.2
Ali, A.M.3
Ho, W.Y.4
Alitheen, N.B.5
Hamid, M.6
-
35
-
-
0028236196
-
Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system
-
7584477
-
Hayden MS, Linsley PS, Gayle MA, Bajorath J, Brady WA, Norris NA, Fell HP, Ledbetter JA, Gilliland LK. Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system. Ther Immunol 1994; 1:3-15; PMID:7584477
-
(1994)
Ther Immunol
, vol.1
, pp. 3-15
-
-
Hayden, M.S.1
Linsley, P.S.2
Gayle, M.A.3
Bajorath, J.4
Brady, W.A.5
Norris, N.A.6
Fell, H.P.7
Ledbetter, J.A.8
Gilliland, L.K.9
-
36
-
-
0028140247
-
Construction, expression, and activity of a bivalent bispecific single-chain antibody
-
8276795
-
Mallender WD, Voss EW, Jr. Construction, expression, and activity of a bivalent bispecific single-chain antibody. J Biol Chem 1994; 269:199-206; PMID:8276795
-
(1994)
J Biol Chem
, vol.269
, pp. 199-206
-
-
Mallender, W.D.1
Voss, E.W.2
-
37
-
-
0028302596
-
Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli
-
8189055
-
Gruber M, Schodin BA, Wilson ER, Kranz DM. Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli. J Immunol 1994; 152:5368-74; PMID:8189055
-
(1994)
J Immunol
, vol.152
, pp. 5368-5374
-
-
Gruber, M.1
Schodin, B.A.2
Wilson, E.R.3
Kranz, D.M.4
-
38
-
-
12444345503
-
CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation
-
12744857
-
Brandao JG, Scheper RK, Lougheed SM, Curiel DT, Tillman BW, Gerritsen WR, van den Eertwegh AJ, Pinedo HM, Haisma HJ, de Gruijl TD. CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation. Vaccine 2003; 21:2268-72; PMID:12744857
-
(2003)
Vaccine
, vol.21
, pp. 2268-2272
-
-
Brandao, J.G.1
Scheper, R.K.2
Lougheed, S.M.3
Curiel, D.T.4
Tillman, B.W.5
Gerritsen, W.R.6
van den Eertwegh, A.J.7
Pinedo, H.M.8
Haisma, H.J.9
de Gruijl, T.D.10
-
39
-
-
10244230493
-
Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv
-
15170735
-
Korn T, Nettelbeck DM, Völkel T, Müller R, Kontermann RE. Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells:a comparative analysis of bacterially expressed single-chain diabody and tandem scFv. J Gene Med 2004; 6:642-51; PMID:15170735; http://dx.doi.org/10.1002/jgm.555
-
(2004)
J Gene Med
, vol.6
, pp. 642-651
-
-
Korn, T.1
Nettelbeck, D.M.2
Völkel, T.3
Müller, R.4
Kontermann, R.E.5
-
40
-
-
0028945817
-
High-affinity antigen binding by chelating recombinant antibodies (CRAbs)
-
7533215
-
Neri D, Momo M, Prospero T, Winter G. High-affinity antigen binding by chelating recombinant antibodies (CRAbs). J Mol Biol 1995; 246:367-73; PMID:7533215; http://dx.doi.org/10.1006/jmbi.1994.0091
-
(1995)
J Mol Biol
, vol.246
, pp. 367-373
-
-
Neri, D.1
Momo, M.2
Prospero, T.3
Winter, G.4
-
41
-
-
0029148633
-
A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity
-
7624362
-
Mack M, Riethmüller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 1995; 92:7021-5; PMID:7624362
-
(1995)
Proc Natl Acad Sci USA
, vol.92
, pp. 7021-7025
-
-
Mack, M.1
Riethmüller, G.2
Kufer, P.3
-
42
-
-
0029614330
-
Production and characterization of bispecific single-chain antibody fragments
-
8643110
-
De Jonge J, Brissinck J, Heirman C, Demanet C, Leo O, Moser M, Thielemans K. Production and characterization of bispecific single-chain antibody fragments. Mol Immunol 1995; 32:1405-12; PMID:8643110
-
(1995)
Mol Immunol
, vol.32
, pp. 1405-1412
-
-
De Jonge, J.1
Brissinck, J.2
Heirman, C.3
Demanet, C.4
Leo, O.5
Moser, M.6
Thielemans, K.7
-
43
-
-
0030772184
-
Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer
-
9435872
-
Kufer P, Mack M, Gruber R, Lutterbüse R, Zettl F, Rietmühler G. Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer. Cancer Immunol Immunother 1997; 45:193-7; PMID:9435872
-
(1997)
Cancer Immunol Immunother
, vol.45
, pp. 193-197
-
-
Kufer, P.1
Mack, M.2
Gruber, R.3
Lutterbüse, R.4
Zettl, F.5
Rietmühler, G.6
-
44
-
-
0035873188
-
Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity
-
11342630
-
McCall AM, Shahied L, Amoroso AR, Horak EM, Simmons HH, Nielson U, Adams GP, Schier R, Marks JD, Weiner LM. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J Immunol 2001; 166:6112-7; PMID:11342630
-
(2001)
J Immunol
, vol.166
, pp. 6112-6117
-
-
McCall, A.M.1
Shahied, L.2
Amoroso, A.R.3
Horak, E.M.4
Simmons, H.H.5
Nielson, U.6
Adams, G.P.7
Schier, R.8
Marks, J.D.9
Weiner, L.M.10
-
45
-
-
2342510193
-
Cloned transgenic farm animals produce a bispecific antibody for T cell-mediated tumor cell killing
-
15105446
-
Grosse-Hovest L, Müller S, Minoia R, Wolf E, Zakhartchenko V, Wenigerkind H, Lassnig C, Besenfelder U, Müller M, Lytton SD, et al. Cloned transgenic farm animals produce a bispecific antibody for T cell-mediated tumor cell killing. Proc Natl Acad Sci USA 2004; 101:6858-63; PMID:15105446; http://dx.doi.org/10.1073/pnas.0308487101
-
(2004)
Proc Natl Acad Sci USA
, vol.101
, pp. 6858-6863
-
-
Grosse-Hovest, L.1
Müller, S.2
Minoia, R.3
Wolf, E.4
Zakhartchenko, V.5
Wenigerkind, H.6
Lassnig, C.7
Besenfelder, U.8
Müller, M.9
Lytton, S.D.10
-
46
-
-
1242291793
-
Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model
-
14983507
-
Ren-Heidenreich L, Davol PA, Kouttab NM, Elfenbein GJ, Lum LG. Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model. Cancer 2004; 100:1095-103; PMID:14983507; http://dx.doi.org/10.1002/cncr.20060
-
(2004)
Cancer
, vol.100
, pp. 1095-1103
-
-
Ren-Heidenreich, L.1
Davol, P.A.2
Kouttab, N.M.3
Elfenbein, G.J.4
Lum, L.G.5
-
47
-
-
0028818097
-
Alternative triggering molecules and singe chain bispecific antibodies
-
8581372
-
Segal DM, Sconocchia G, Titus JA, Jost CR, Kurucz I. Alternative triggering molecules and singe chain bispecific antibodies. J Hematother 1995; 4:377-82; PMID:8581372; http://dx.doi.org/10.1089/scd.1.1995.4.377
-
(1995)
J Hematother
, vol.4
, pp. 377-382
-
-
Segal, D.M.1
Sconocchia, G.2
Titus, J.A.3
Jost, C.R.4
Kurucz, I.5
-
48
-
-
0742307269
-
Characterization of an anti-human ovarian carcinomaxanti-human CD3 bispecific single-chain antibody with an albumin-original interlinker
-
14751149
-
Fang M, Zhao R, Yang Z, Zhang Z, Li H, Zhang XT, Lin Q, Huang HL. Characterization of an anti-human ovarian carcinomaxanti-human CD3 bispecific single-chain antibody with an albumin-original interlinker. Gynecol Oncol 2004; 92:135-46; PMID:14751149
-
(2004)
Gynecol Oncol
, vol.92
, pp. 135-146
-
-
Fang, M.1
Zhao, R.2
Yang, Z.3
Zhang, Z.4
Li, H.5
Zhang, X.T.6
Lin, Q.7
Huang, H.L.8
-
49
-
-
84946924445
-
Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells
-
26566946
-
Schmohl JU, Gleason MK, Dougherty PR, Miller JS, Vallera DA. Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells. Target Oncol 2016; 11:353-61; PMID:26566946; http://dx.doi.org/10.1007/s11523-015-0391-8
-
(2016)
Target Oncol
, vol.11
, pp. 353-361
-
-
Schmohl, J.U.1
Gleason, M.K.2
Dougherty, P.R.3
Miller, J.S.4
Vallera, D.A.5
-
50
-
-
26244466523
-
BiTEs: bispecific antibody constructs with unique anti-tumor activity
-
16213416
-
Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA. BiTEs:bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today 2005; 10:1237-44; PMID:16213416; http://dx.doi.org/10.1016/S1359-6446(05)03554-3
-
(2005)
Drug Discov Today
, vol.10
, pp. 1237-1244
-
-
Wolf, E.1
Hofmeister, R.2
Kufer, P.3
Schlereth, B.4
Baeuerle, P.A.5
-
51
-
-
67449156132
-
Bispecific T-cell engaging antibodies for cancer therapy
-
19509221
-
Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009; 69:4941-4; PMID:19509221; http://dx.doi.org/10.1158/0008-5472.CAN-09-0547
-
(2009)
Cancer Res
, vol.69
, pp. 4941-4944
-
-
Baeuerle, P.A.1
Reinhardt, C.2
-
52
-
-
84925091940
-
Bispecific T-cell engagers for cancer immunotherapy
-
25367186
-
Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol 2015; 93:290-6; PMID:25367186; http://dx.doi.org/10.1038/icb.2014.93
-
(2015)
Immunol Cell Biol
, vol.93
, pp. 290-296
-
-
Huehls, A.M.1
Coupet, T.A.2
Sentman, C.L.3
-
53
-
-
84867858547
-
Blinatumomab: a historical perspective
-
22940266
-
Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Blinatumomab:a historical perspective. Pharmcol Ther 2012; 136:334-42; PMID:22940266; http://dx.doi.org/10.1016/j.pharmthera.2012.07.013
-
(2012)
Pharmcol Ther
, vol.136
, pp. 334-342
-
-
Nagorsen, D.1
Kufer, P.2
Baeuerle, P.A.3
Bargou, R.4
-
54
-
-
84936934575
-
Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer
-
25971805
-
Stieglmaier J, Benjamin J, Nagorsen D. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer. Expert Opin Biol Ther 2015; 15:1093-9; PMID:25971805; http://dx.doi.org/10.1517/14712598.2015.1041373
-
(2015)
Expert Opin Biol Ther
, vol.15
, pp. 1093-1099
-
-
Stieglmaier, J.1
Benjamin, J.2
Nagorsen, D.3
-
55
-
-
84975474128
-
A review of blinatumomab, a novel immunotherapy
-
26607163
-
Newman MJ, Benani DJ. A review of blinatumomab, a novel immunotherapy. J Oncol Pharm Pract 2016; 22:639-45; PMID:26607163; http://dx.doi.org/10.1177/1078155215618770
-
(2016)
J Oncol Pharm Pract
, vol.22
, pp. 639-645
-
-
Newman, M.J.1
Benani, D.J.2
-
56
-
-
84863522243
-
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
-
22592608
-
Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, Gökbuget N, Neumann S, Goebeler M, Viardot A, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012; 119:6226-33; PMID:22592608; http://dx.doi.org/10.1182/blood-2012-01-400515
-
(2012)
Blood
, vol.119
, pp. 6226-6233
-
-
Klinger, M.1
Brandl, C.2
Zugmaier, G.3
Hijazi, Y.4
Bargou, R.C.5
Topp, M.S.6
Gökbuget, N.7
Neumann, S.8
Goebeler, M.9
Viardot, A.10
-
57
-
-
84926099033
-
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
-
25524800
-
Topp MS, Gökbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, Dombret H, Fielding AK, Heffner L, Larson RA, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia:a multicentre, single-arm, phase 2 study. Lancet Oncol 2015; 16:57-66; PMID:25524800; http://dx.doi.org/10.1016/S1470-2045(14)71170-2
-
(2015)
Lancet Oncol
, vol.16
, pp. 57-66
-
-
Topp, M.S.1
Gökbuget, N.2
Stein, A.S.3
Zugmaier, G.4
O'Brien, S.5
Bargou, R.C.6
Dombret, H.7
Fielding, A.K.8
Heffner, L.9
Larson, R.A.10
-
58
-
-
85026147994
-
A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells
-
18833000
-
Kellner C, Bruenke J, Stieglmaier J, Schwemmlein M, Schwenkert M, Singer H, Mentz K, Peipp M, Lang P, Oduncu F, et al. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells. J. Immunother 2008; 31:871-84; PMID:18833000
-
(2008)
J. Immunother
, vol.31
, pp. 871-884
-
-
Kellner, C.1
Bruenke, J.2
Stieglmaier, J.3
Schwemmlein, M.4
Schwenkert, M.5
Singer, H.6
Mentz, K.7
Peipp, M.8
Lang, P.9
Oduncu, F.10
-
59
-
-
78651404837
-
A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting
-
21081841
-
Schubert I, Kellner C, Stein C, Kügler M, Schwenkert M, Saul D, Mentz K, Singer H, Stockmeyer B, Hillen W, et al. A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting. MAbs 2011; 3:21-30; PMID:21081841
-
(2011)
MAbs
, vol.3
, pp. 21-30
-
-
Schubert, I.1
Kellner, C.2
Stein, C.3
Kügler, M.4
Schwenkert, M.5
Saul, D.6
Mentz, K.7
Singer, H.8
Stockmeyer, B.9
Hillen, W.10
-
60
-
-
84954350338
-
Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody
-
26137406
-
Ahmed M, Cheng M, Cheung IY, Cheung NK. Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody. Oncoimmunology 2015; 4:e989776; PMID:26137406
-
(2015)
Oncoimmunology
, vol.4
, pp. e989776
-
-
Ahmed, M.1
Cheng, M.2
Cheung, I.Y.3
Cheung, N.K.4
-
61
-
-
77955782190
-
A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting
-
20636437
-
Kügler M, Stein C, Kellner C, Mentz K, Saul D, Schwenkert M, Schubert I.Singer H, Oduncu F, Stockmeyer B, et al. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Br J Haematol 2010; 150:574-586; PMID:20636437
-
(2010)
Br J Haematol
, vol.150
, pp. 574-586
-
-
Kügler, M.1
Stein, C.2
Kellner, C.3
Mentz, K.4
Saul, D.5
Schwenkert, M.6
Schubert, I.7
Singer, H.8
Oduncu, F.9
Stockmeyer, B.10
-
62
-
-
77954996067
-
VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist single-chain diabody
-
20576629
-
Igawa T, Tsunoda H, Kikuchi Y, Yoshida M, Tanaka M, Koga A, Sekimori Y, Orita T, Aso Y, Hattori K, et al. VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist single-chain diabody. Protein Eng DesSel 2010; 23:667-77; PMID:20576629; http://dx.doi.org/10.1093/protein/gzq034
-
(2010)
Protein Eng DesSel
, vol.23
, pp. 667-677
-
-
Igawa, T.1
Tsunoda, H.2
Kikuchi, Y.3
Yoshida, M.4
Tanaka, M.5
Koga, A.6
Sekimori, Y.7
Orita, T.8
Aso, Y.9
Hattori, K.10
-
63
-
-
84882339603
-
The emerging role of new protein scaffold-based agents for treatment of cancer
-
23893924
-
Weidle UH, Auer J, Brinkmann U, Georges G, Tiefenthaler G. The emerging role of new protein scaffold-based agents for treatment of cancer. Cancer Genomics Proteomics 2013; 10:155-68; PMID:23893924
-
(2013)
Cancer Genomics Proteomics
, vol.10
, pp. 155-168
-
-
Weidle, U.H.1
Auer, J.2
Brinkmann, U.3
Georges, G.4
Tiefenthaler, G.5
-
64
-
-
54849403487
-
Single-domain antibodies as building blocks for novel therapeutics
-
18691671
-
Saerens D, Ghassebeh GH, Muyldermans S. Single-domain antibodies as building blocks for novel therapeutics. Curr Opin Pharmacol 2008; 8:600-8; PMID:18691671; http://dx.doi.org/10.1016/j.coph.2008.07.006
-
(2008)
Curr Opin Pharmacol
, vol.8
, pp. 600-608
-
-
Saerens, D.1
Ghassebeh, G.H.2
Muyldermans, S.3
-
65
-
-
0035831483
-
Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs
-
11053416
-
Conrath EK, Lauwereys M, Wyns L, Muyldermans S. Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem 2001; 276:7346-50; PMID:11053416
-
(2001)
J Biol Chem
, vol.276
, pp. 7346-7350
-
-
Conrath, E.K.1
Lauwereys, M.2
Wyns, L.3
Muyldermans, S.4
-
66
-
-
33748784077
-
Dimerisation strategies for shark IgNAR single domain antibody fragments
-
16962608
-
Simmons DP, Abregu FA, Krishnan UV, Proll DF, Streltsov VA, Doughty L, Hattarki MK, Nuttall SD. Dimerisation strategies for shark IgNAR single domain antibody fragments. J Immunol Methods 2006; 315:171-84; PMID:16962608; http://dx.doi.org/10.1016/j.jim.2006.07.019
-
(2006)
J Immunol Methods
, vol.315
, pp. 171-184
-
-
Simmons, D.P.1
Abregu, F.A.2
Krishnan, U.V.3
Proll, D.F.4
Streltsov, V.A.5
Doughty, L.6
Hattarki, M.K.7
Nuttall, S.D.8
-
67
-
-
33845641402
-
Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis
-
17152019
-
De Bernardis F, Liu H, O'Mahony R, La Valle R, Bartollino S, Sandini S, Grant S, Brewis N, Tomlinson I, Basset RC, et al. Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis. J Infect Dis 2007; 195:149-57; PMID:17152019; http://dx.doi.org/10.1086/509891
-
(2007)
J Infect Dis
, vol.195
, pp. 149-157
-
-
De Bernardis, F.1
Liu, H.2
O'Mahony, R.3
La Valle, R.4
Bartollino, S.5
Sandini, S.6
Grant, S.7
Brewis, N.8
Tomlinson, I.9
Basset, R.C.10
-
68
-
-
84907102875
-
A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice
-
24683195
-
Yang Z, Schmidt D, Liu W, Li S, Shi L, Sheng J, Chen K, Yu H, Tremblay JM, Chen X, et al. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. J Infect Dis 2014; 210:964-72; PMID:24683195; http://dx.doi.org/10.1093/infdis/jiu196
-
(2014)
J Infect Dis
, vol.210
, pp. 964-972
-
-
Yang, Z.1
Schmidt, D.2
Liu, W.3
Li, S.4
Shi, L.5
Sheng, J.6
Chen, K.7
Yu, H.8
Tremblay, J.M.9
Chen, X.10
-
69
-
-
84934900766
-
The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis
-
25994180
-
Van Roy M, Ververken C, Beirnaert E, Hoefman S, Kolkman J, Vierboom M, Breedveld E, 't Hart B, Poelmans S, Bontinck L, et al. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther 2015; 17:135; PMID:25994180; http://dx.doi.org/10.1186/s13075-015-0651-0
-
(2015)
Arthritis Res Ther
, vol.17
, pp. 135
-
-
Van Roy, M.1
Ververken, C.2
Beirnaert, E.3
Hoefman, S.4
Kolkman, J.5
Vierboom, M.6
Breedveld, E.7
't Hart, B.8
Poelmans, S.9
Bontinck, L.10
-
70
-
-
51649091611
-
Passive immunization of pigs with bispecific llama single-domain antibody fragments against foot-and-mouth disease and porcine immunoglobulin
-
18534789
-
Harmsen MM, Fijten HP, Dekker A, Eblé PL. Passive immunization of pigs with bispecific llama single-domain antibody fragments against foot-and-mouth disease and porcine immunoglobulin. Vet Microbiol 2008; 132:56-64; PMID:18534789; http://dx.doi.org/10.1016/j.vetmic.2008.04.030
-
(2008)
Vet Microbiol
, vol.132
, pp. 56-64
-
-
Harmsen, M.M.1
Fijten, H.P.2
Dekker, A.3
Eblé, P.L.4
-
71
-
-
0027197493
-
Diabodies:” small bivalent and bispecific antibody fragments
-
8341653
-
Holliger P, Prospero T, Winter G. “Diabodies:” small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993; 90:6444-8; PMID:8341653
-
(1993)
Proc Natl Acad Sci USA
, vol.90
, pp. 6444-6448
-
-
Holliger, P.1
Prospero, T.2
Winter, G.3
-
72
-
-
76049090707
-
Diabodies: molecular engineering and therapeutic applications
-
20016854
-
Wu C. Diabodies:molecular engineering and therapeutic applications. Drug News Perspect 2009; 22:453-8; PMID:20016854
-
(2009)
Drug News Perspect
, vol.22
, pp. 453-458
-
-
Wu, C.1
-
73
-
-
0028774708
-
Crystal structure of a diabody, a bivalent antibody fragment
-
7704531
-
Perisic O, Webb PA, Holliger P, Winter G, Williams RL. Crystal structure of a diabody, a bivalent antibody fragment. Structure 1994; 2:1217-26; PMID:7704531
-
(1994)
Structure
, vol.2
, pp. 1217-1226
-
-
Perisic, O.1
Webb, P.A.2
Holliger, P.3
Winter, G.4
Williams, R.L.5
-
74
-
-
0029932582
-
Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody
-
8736497
-
Holliger P, Brissinck J, Williams RL, Thielemans K, Winter G. Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Protein Eng 1996; 9:299-305; PMID:8736497
-
(1996)
Protein Eng
, vol.9
, pp. 299-305
-
-
Holliger, P.1
Brissinck, J.2
Williams, R.L.3
Thielemans, K.4
Winter, G.5
-
75
-
-
0030434862
-
Design and expression of a stable bispecific scFv dimer with affinity for both glycophorin and N9 neuraminidase
-
9171890
-
Atwell JL, Pearce LA, Lah M, Gruen LC, Kortt AA, Hudson PJ. Design and expression of a stable bispecific scFv dimer with affinity for both glycophorin and N9 neuraminidase. Mol Immunol 1996; 33:1301-12; PMID:9171890
-
(1996)
Mol Immunol
, vol.33
, pp. 1301-1312
-
-
Atwell, J.L.1
Pearce, L.A.2
Lah, M.3
Gruen, L.C.4
Kortt, A.A.5
Hudson, P.J.6
-
76
-
-
0030743802
-
Complement recruitment using bispecific diabodies
-
9219263
-
Kontermann RE, Wing MG, Winter G. Complement recruitment using bispecific diabodies. Nat Biotechnol 1997; 15:629-31; PMID:9219263; http://dx.doi.org/10.1038/nbt0797-629
-
(1997)
Nat Biotechnol
, vol.15
, pp. 629-631
-
-
Kontermann, R.E.1
Wing, M.G.2
Winter, G.3
-
77
-
-
0030795887
-
Enzyme immunoassays using bispecific diabodies
-
9237098
-
Kontermann RE, Martineau P, Cummings CE, Karpas A, Allen D, Derbyshire E, Winter G. Enzyme immunoassays using bispecific diabodies. Immunotechnology 1997; 3:137-44; PMID:9237098
-
(1997)
Immunotechnology
, vol.3
, pp. 137-144
-
-
Kontermann, R.E.1
Martineau, P.2
Cummings, C.E.3
Karpas, A.4
Allen, D.5
Derbyshire, E.6
Winter, G.7
-
78
-
-
0034662632
-
Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation
-
10969772
-
Cochlovius B, Kipriyanov SM, Stassar MJ, Schuhmacher J, Benner A, Moldenhauer G, Little M. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation. Cancer Res 2000; 60:4336-41; PMID:10969772
-
(2000)
Cancer Res
, vol.60
, pp. 4336-4341
-
-
Cochlovius, B.1
Kipriyanov, S.M.2
Stassar, M.J.3
Schuhmacher, J.4
Benner, A.5
Moldenhauer, G.6
Little, M.7
-
79
-
-
0035660721
-
Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy
-
11789029
-
DeNardo DG, Xiong CY, Shi XB, DeNardo GL, DeNardo SJ. Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform:bispecific antibodies for pretargeted radioimmunotherapy. Cancer Biother Radiopharm 2001; 16:525-35; PMID:11789029; http://dx.doi.org/10.1089/10849780152752128
-
(2001)
Cancer Biother Radiopharm
, vol.16
, pp. 525-535
-
-
DeNardo, D.G.1
Xiong, C.Y.2
Shi, X.B.3
DeNardo, G.L.4
DeNardo, S.J.5
-
80
-
-
2142662111
-
The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody
-
15120630
-
Lu D, Jimenez X, Witte L, Zhu Z. The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody. Biochem Biophys Res Commun 2004; 318:507-13; PMID:15120630; http://dx.doi.org/10.1016/j.bbrc.2004.04.060
-
(2004)
Biochem Biophys Res Commun
, vol.318
, pp. 507-513
-
-
Lu, D.1
Jimenez, X.2
Witte, L.3
Zhu, Z.4
-
81
-
-
0033506366
-
High avidity scFv multimers: diabodies and triabodies
-
10648937
-
Hudson PJ, Kortt AA. High avidity scFv multimers:diabodies and triabodies. J Immunol Meth 1999; 231:177-89; PMID:10648937
-
(1999)
J Immunol Meth
, vol.231
, pp. 177-189
-
-
Hudson, P.J.1
Kortt, A.A.2
-
82
-
-
0032801102
-
Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding
-
10403395
-
Le Gall F, Kipriyanov SM, Moldenhauer G, Little M. Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19:effect of valency on cell binding. FEBS Lett 1999; 453:164-8; PMID:10403395
-
(1999)
FEBS Lett
, vol.453
, pp. 164-168
-
-
Le Gall, F.1
Kipriyanov, S.M.2
Moldenhauer, G.3
Little, M.4
-
83
-
-
0038004731
-
Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies
-
12818205
-
Kipriyanov SM, Moldenhauer G, Braunagel M, Reusch U, Cochlovius B, Le Gall F, Kouprianova OA, Von der Lieth CW, Little M. Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies. J Mol Biol 2003; 330:99-111; PMID:12818205
-
(2003)
J Mol Biol
, vol.330
, pp. 99-111
-
-
Kipriyanov, S.M.1
Moldenhauer, G.2
Braunagel, M.3
Reusch, U.4
Cochlovius, B.5
Le Gall, F.6
Kouprianova, O.A.7
Von der Lieth, C.W.8
Little, M.9
-
84
-
-
0031441221
-
Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris
-
9488147
-
Fitzgerald K, Holliger P, Winter G. Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris. Protein Eng 1997; 10:1221-5; PMID:9488147
-
(1997)
Protein Eng
, vol.10
, pp. 1221-1225
-
-
Fitzgerald, K.1
Holliger, P.2
Winter, G.3
-
85
-
-
0030909820
-
Remodeling domain interfaces to enhance heterodimer formation
-
9098887
-
Zhu Z, Presta LG, Zapata G, Carter P. Remodeling domain interfaces to enhance heterodimer formation. Protein Sci 1997; 6:781-8; PMID:9098887; http://dx.doi.org/10.1002/pro.5560060404
-
(1997)
Protein Sci
, vol.6
, pp. 781-788
-
-
Zhu, Z.1
Presta, L.G.2
Zapata, G.3
Carter, P.4
-
86
-
-
0034529142
-
Expression of a bispecific dsFv-dsFv' antibody fragment in Escherichia coli
-
11112512
-
Schmiedl A, Breitling F, Dübel S. Expression of a bispecific dsFv-dsFv' antibody fragment in Escherichia coli. Protein Eng 2000; 13:725-34; PMID:11112512
-
(2000)
Protein Eng
, vol.13
, pp. 725-734
-
-
Schmiedl, A.1
Breitling, F.2
Dübel, S.3
-
87
-
-
0032844812
-
Enzyme recruitment and tumor cell killing in vitro by a secreted bispecific single-chain diabody
-
Brüsselbach S, Korn T, Völkel T, Müller R, Kontermann RE. Enzyme recruitment and tumor cell killing in vitro by a secreted bispecific single-chain diabody. Tumor Targeting. 1999; 4:115-23
-
(1999)
Tumor Targeting
, vol.4
, pp. 115-123
-
-
Brüsselbach, S.1
Korn, T.2
Völkel, T.3
Müller, R.4
Kontermann, R.E.5
-
88
-
-
1442286971
-
Bispecific single-chain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes
-
14770081
-
Korn T, Müller R, Kontermann RE. Bispecific single-chain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes. J Immunother 2004; 27:99-106; PMID:14770081
-
(2004)
J Immunother
, vol.27
, pp. 99-106
-
-
Korn, T.1
Müller, R.2
Kontermann, R.E.3
-
89
-
-
0035664509
-
Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies
-
11739902
-
Völkel T, Korn T, Bach M, Müller R, Kontermann RE. Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies. Protein Eng 2001; 14:815-23; PMID:11739902
-
(2001)
Protein Eng
, vol.14
, pp. 815-823
-
-
Völkel, T.1
Korn, T.2
Bach, M.3
Müller, R.4
Kontermann, R.E.5
-
90
-
-
81955161920
-
Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module
-
22014687
-
Stamova S, Cartellieri M, Feldmann A, Arndt C, Koristka S, Bartsch H, Bippes CC, Wehner R, Schmitz M, von Bonin M, et al. Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module. Mol Immunol 2011; 49:474-82; PMID:22014687; http://dx.doi.org/10.1016/j.molimm.2011.09.019
-
(2011)
Mol Immunol
, vol.49
, pp. 474-482
-
-
Stamova, S.1
Cartellieri, M.2
Feldmann, A.3
Arndt, C.4
Koristka, S.5
Bartsch, H.6
Bippes, C.C.7
Wehner, R.8
Schmitz, M.9
von Bonin, M.10
-
91
-
-
0033569478
-
Bispecific tandem diabodies for tumor therapy with improved antigen binding and pharmacokinetics
-
10512714
-
Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, von der Lieth CW, Matys ER, Little M. Bispecific tandem diabodies for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol 1999; 293:41-56; PMID:10512714
-
(1999)
J Mol Biol
, vol.293
, pp. 41-56
-
-
Kipriyanov, S.M.1
Moldenhauer, G.2
Schuhmacher, J.3
Cochlovius, B.4
von der Lieth, C.W.5
Matys, E.R.6
Little, M.7
-
92
-
-
4143137525
-
Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody
-
15126676
-
Le Gall F, Reusch U, Little M, Kipriyanov SM. Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. Protein Eng Des Sel 2004; 17:357-66; PMID:15126676; http://dx.doi.org/10.1093/protein/gzh039
-
(2004)
Protein Eng Des Sel
, vol.17
, pp. 357-366
-
-
Le Gall, F.1
Reusch, U.2
Little, M.3
Kipriyanov, S.M.4
-
93
-
-
84899744468
-
A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells
-
24670809
-
Reusch U, Burkhardt C, Fucet I, Le Gall F, Le Gall M, Hoffmann K, Knackmuss SH, Kiprijanov S, Little M, Zhukovsky EA. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells. MAbs 2014; 6:728-39; PMID:24670809; http://dx.doi.org/10.4161/mabs.28591
-
(2014)
MAbs
, vol.6
, pp. 728-739
-
-
Reusch, U.1
Burkhardt, C.2
Fucet, I.3
Le Gall, F.4
Le Gall, M.5
Hoffmann, K.6
Knackmuss, S.H.7
Kiprijanov, S.8
Little, M.9
Zhukovsky, E.A.10
-
94
-
-
84933505755
-
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
-
25887777
-
Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, Dietlein M, Kuhnert G, Kessler J, Buerkle C. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood 2015; 125:4024-31; PMID:25887777; http://dx.doi.org/10.1182/blood-2014-12-614636
-
(2015)
Blood
, vol.125
, pp. 4024-4031
-
-
Rothe, A.1
Sasse, S.2
Topp, M.S.3
Eichenauer, D.A.4
Hummel, H.5
Reiners, K.S.6
Dietlein, M.7
Kuhnert, G.8
Kessler, J.9
Buerkle, C.10
-
95
-
-
85006325284
-
Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia
-
Epub ahead of print, 27189165
-
Reusch U, Harrington K, Gudgeon C, Fucek I, Ellwanger K, Weichel M, Knackmuss SH, Zhukovsky EA, Fox JA, Kunkel LA, et al. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia. Clin Cancer Res 2016; 22(23):5829-38; Epub ahead of print; PMID:27189165; http://dx.doi.org/10.1158/1078-0432.CCR-16-0350
-
(2016)
Clin Cancer Res
, vol.22
, Issue.23
, pp. 5829-5838
-
-
Reusch, U.1
Harrington, K.2
Gudgeon, C.3
Fucek, I.4
Ellwanger, K.5
Weichel, M.6
Knackmuss, S.H.7
Zhukovsky, E.A.8
Fox, J.A.9
Kunkel, L.A.10
-
96
-
-
77954757304
-
Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion
-
20382161
-
Johnson S, Burke S, Huang L, Gorlatov S, Li H, Wang W, Zhang W, Tuaillon N, Rainey J, Barat B, et al. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J Mol Biol 2010; 399:436-449; PMID:20382161; http://dx.doi.org/10.1016/j.jmb.2010.04.001
-
(2010)
J Mol Biol
, vol.399
, pp. 436-449
-
-
Johnson, S.1
Burke, S.2
Huang, L.3
Gorlatov, S.4
Li, H.5
Wang, W.6
Zhang, W.7
Tuaillon, N.8
Rainey, J.9
Barat, B.10
-
97
-
-
84969378904
-
Preclinical activity and safety of MGD006, a CD123xCD3 bispecific DART molecule for the treatment of hematological malignancies
-
Moore P, Chichili GR, Huang L, Li H, Burke S, Chen F, et al. Preclinical activity and safety of MGD006, a CD123xCD3 bispecific DART molecule for the treatment of hematological malignancies. Eur J Cancer 2014; 50:48
-
(2014)
Eur J Cancer
, vol.50
, pp. 48
-
-
Moore, P.1
Chichili, G.R.2
Huang, L.3
Li, H.4
Burke, S.5
Chen, F.6
-
98
-
-
84880385914
-
Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus
-
23658441
-
Brien JD, Sukupolvi-Petty S, Williams KL, Lam CY, Schmid MA, Johnson S, Harris E, Diamond MS. Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus. J. Virol 2013; 87:7747-53; PMID:23658441; http://dx.doi.org/10.1128/JVI.00327-13
-
(2013)
J. Virol
, vol.87
, pp. 7747-7753
-
-
Brien, J.D.1
Sukupolvi-Petty, S.2
Williams, K.L.3
Lam, C.Y.4
Schmid, M.A.5
Johnson, S.6
Harris, E.7
Diamond, M.S.8
-
99
-
-
0141679540
-
Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy
-
14506187
-
Rossi EA, Sharkey RM, McBridge W, Karacay H, Zeng L, Hansen HJ, Goldenberg DM, Chang CH. Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. Clin Cancer Res 2003; 9:3886S-96S; PMID:14506187
-
(2003)
Clin Cancer Res
, vol.9
, pp. 3886S-38896S
-
-
Rossi, E.A.1
Sharkey, R.M.2
McBridge, W.3
Karacay, H.4
Zeng, L.5
Hansen, H.J.6
Goldenberg, D.M.7
Chang, C.H.8
-
100
-
-
26444530095
-
Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells
-
16203811
-
Rossi EA, Chang CH, Losman MJ, Sharkey RM, Karacay H, McBridge W, Cardillo TM, Hansen HJ, Qu Z, Horak ID, et al. Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells. Clin Cancer Res 2005; 11:7122s-9s; PMID:16203811; http://dx.doi.org/10.1158/1078-0432.CCR-1004-0020
-
(2005)
Clin Cancer Res
, vol.11
, pp. 7122s-7129s
-
-
Rossi, E.A.1
Chang, C.H.2
Losman, M.J.3
Sharkey, R.M.4
Karacay, H.5
McBridge, W.6
Cardillo, T.M.7
Hansen, H.J.8
Qu, Z.9
Horak, I.D.10
-
101
-
-
0034671764
-
Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives
-
11120833
-
Schoonjans R, Willems A, Schoonooghe S, Fiers W, Grooten J, Mertens N. Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives. J Immunol 2000; 165:7050-7; PMID:11120833
-
(2000)
J Immunol
, vol.165
, pp. 7050-7057
-
-
Schoonjans, R.1
Willems, A.2
Schoonooghe, S.3
Fiers, W.4
Grooten, J.5
Mertens, N.6
-
102
-
-
0035043050
-
A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain
-
11337278
-
Schoonjans R, Willems A, Schoonooghe S, Leoen J, Grooten J, Mertenss N. A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain. Biomol Eng 2001; 17:193-202; PMID:11337278
-
(2001)
Biomol Eng
, vol.17
, pp. 193-202
-
-
Schoonjans, R.1
Willems, A.2
Schoonooghe, S.3
Leoen, J.4
Grooten, J.5
Mertenss, N.6
-
103
-
-
0037106007
-
Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments
-
12165442
-
Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z. Fab-scFv fusion protein:an efficient approach to production of bispecific antibody fragments. J Immunol Methods 2002; 267:213-26; PMID:12165442
-
(2002)
J Immunol Methods
, vol.267
, pp. 213-226
-
-
Lu, D.1
Jimenez, X.2
Zhang, H.3
Bohlen, P.4
Witte, L.5
Zhu, Z.6
-
104
-
-
41349118741
-
Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action
-
18025153
-
Qu Z, Goldenberg DM, Cardillo TM, Shi V, Hansen HJ, Chang CH. Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. Blood 2008; 111:2211-9; PMID:18025153; http://dx.doi.org/10.1182/blood-2007-08-110072
-
(2008)
Blood
, vol.111
, pp. 2211-2219
-
-
Qu, Z.1
Goldenberg, D.M.2
Cardillo, T.M.3
Shi, V.4
Hansen, H.J.5
Chang, C.H.6
-
105
-
-
79952038441
-
Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells
-
21339041
-
Kellner C, Bruenke J, Horner H, Schubert J, Schwenkert M, Mentz K, Barbin K, Stein C, Peipp M, Stockmeyer B, et al. Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells. Cancer Lett 2011; 303:128-39; PMID:21339041; http://dx.doi.org/10.1016/j.canlet.2011.01.020
-
(2011)
Cancer Lett
, vol.303
, pp. 128-139
-
-
Kellner, C.1
Bruenke, J.2
Horner, H.3
Schubert, J.4
Schwenkert, M.5
Mentz, K.6
Barbin, K.7
Stein, C.8
Peipp, M.9
Stockmeyer, B.10
-
106
-
-
84885016617
-
Quantification of cell surface proteins with bispecific antibodies
-
23960142
-
Panke C, Weiniger D, Haas A, Schelter F, Schlothauer T, Bader S, Sircar R, Josel HP, Baer U, Burtscher H, et al. Quantification of cell surface proteins with bispecific antibodies. Protein Eng Des Sel 2013; 26:645-54; PMID:23960142; http://dx.doi.org/10.1093/protein/gzt035
-
(2013)
Protein Eng Des Sel
, vol.26
, pp. 645-654
-
-
Panke, C.1
Weiniger, D.2
Haas, A.3
Schelter, F.4
Schlothauer, T.5
Bader, S.6
Sircar, R.7
Josel, H.P.8
Baer, U.9
Burtscher, H.10
-
107
-
-
0031059402
-
Design and production of novel tetravalent bispecific antibodies
-
9035142
-
Coloma MJ, Morrison SL. Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol 1997; 15:159-63; PMID:9035142; http://dx.doi.org/10.1038/nbt0297-159
-
(1997)
Nat Biotechnol
, vol.15
, pp. 159-163
-
-
Coloma, M.J.1
Morrison, S.L.2
-
108
-
-
84964776843
-
A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells
-
27112931
-
Li A, Xing J, Li L, Zhou C, Dong B, He P, Li Q, Wang Z. A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells. AMB Express 2016; 6:32; PMID:27112931; http://dx.doi.org/10.1186/s13568-016-0201-4
-
(2016)
AMB Express
, vol.6
, pp. 32
-
-
Li, A.1
Xing, J.2
Li, L.3
Zhou, C.4
Dong, B.5
He, P.6
Li, Q.7
Wang, Z.8
-
109
-
-
84947460200
-
TriFabs - Trivalent IgG-Shaped Bispecific Antibody Derivatives: Design, Generation, Characterization and Application for Targeted Payload Delivery
-
26593903
-
Mayer K, Baumann AL, Grote M, Seeber S, Kettenberger H, Breuer S, Killian T, Schäfer W, Brinkmann U. TriFabs - Trivalent IgG-Shaped Bispecific Antibody Derivatives:Design, Generation, Characterization and Application for Targeted Payload Delivery. Int J Mol Sci 2015; 16:27497-4507; PMID:26593903; http://dx.doi.org/10.3390/ijms161126037
-
(2015)
Int J Mol Sci
, vol.16
, pp. 27497-27507
-
-
Mayer, K.1
Baumann, A.L.2
Grote, M.3
Seeber, S.4
Kettenberger, H.5
Breuer, S.6
Killian, T.7
Schäfer, W.8
Brinkmann, U.9
-
110
-
-
0027183934
-
A recombinant immunotoxin containing a disulfide-stabilized Fv fragment
-
8356052
-
Brinkmann U, Reiter Y, Jung SH, Lee B, Pastan I. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc Natl Acad Sci USA 1993; 90:7538-42; PMID:8356052
-
(1993)
Proc Natl Acad Sci USA
, vol.90
, pp. 7538-7542
-
-
Brinkmann, U.1
Reiter, Y.2
Jung, S.H.3
Lee, B.4
Pastan, I.5
-
111
-
-
0029766875
-
Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments
-
9631086
-
Reiter Y, Brinkmann U, Lee B, Pastan I. Engineering antibody Fv fragments for cancer detection and therapy:disulfide-stabilized Fv fragments. Nat Biotechnol 1996; 14:1239-45; PMID:9631086
-
(1996)
Nat Biotechnol
, vol.14
, pp. 1239-1245
-
-
Reiter, Y.1
Brinkmann, U.2
Lee, B.3
Pastan, I.4
-
112
-
-
84945176688
-
Fab-based bispecific antibody formats with robust biophysical properties and biological activity
-
25774965
-
Wu X, Sereno AJ, Huang F, Lewis SM, Lieu RL, Weldon C, Torres C, Fine C, Batt MA, Fitchett JR, et al. Fab-based bispecific antibody formats with robust biophysical properties and biological activity. MAbs 2015, 7:470-82; PMID:25774965; http://dx.doi.org/10.1080/19420862.2015.1022694
-
(2015)
MAbs
, vol.7
, pp. 470-482
-
-
Wu, X.1
Sereno, A.J.2
Huang, F.3
Lewis, S.M.4
Lieu, R.L.5
Weldon, C.6
Torres, C.7
Fine, C.8
Batt, M.A.9
Fitchett, J.R.10
-
113
-
-
84982295378
-
Fab-dsFv: a bispecific antibody format with extended serum half-life through albumin binding
-
epub ahead of print, 27532598
-
Davé E, Adams R, Zaccheo O, Carrington B, Composn JE, Dugdale S, Airey M, Malcolm S, Hailu H, Wild G, et al. Fab-dsFv:a bispecific antibody format with extended serum half-life through albumin binding. MAbs 2016; 8(7):1319-35; epub ahead of print; PMID:27532598; http://dx.doi.org/10.1080/19420862.2016.1210747
-
(2016)
MAbs
, vol.8
, Issue.7
, pp. 1319-1335
-
-
Davé, E.1
Adams, R.2
Zaccheo, O.3
Carrington, B.4
Composn, J.E.5
Dugdale, S.6
Airey, M.7
Malcolm, S.8
Hailu, H.9
Wild, G.10
-
114
-
-
84899933079
-
ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells
-
24531387
-
Bossi G, Buisson S, Oates J, Jakobsen BK, Hassan NJ. ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells. Cancer Immunol Immunother 2014; 63:437-48; PMID:24531387; http://dx.doi.org/10.1007/s00262-014-1525-z
-
(2014)
Cancer Immunol Immunother
, vol.63
, pp. 437-448
-
-
Bossi, G.1
Buisson, S.2
Oates, J.3
Jakobsen, B.K.4
Hassan, N.J.5
-
115
-
-
84929821227
-
ImmTACs for targeted cancer therapy: Why, what, how, and which
-
25708206
-
Oates J, Hassan NK, Jakobsen BK. ImmTACs for targeted cancer therapy:Why, what, how, and which. Mol Immunol 2015; 67:67-74; PMID:25708206; http://dx.doi.org/10.1016/j.molimm.2015.01.024
-
(2015)
Mol Immunol
, vol.67
, pp. 67-74
-
-
Oates, J.1
Hassan, N.K.2
Jakobsen, B.K.3
-
116
-
-
0142215405
-
Stable soluble T-cell receptor molecules for crystallization and therapeutics
-
14560057
-
Boulter JM, Glick M, Todorov PT, Baston E, Sami M, Rizkallah P, Jakobsen BK. Stable soluble T-cell receptor molecules for crystallization and therapeutics. Protein Eng 2003; 16:707-11; PMID:14560057
-
(2003)
Protein Eng
, vol.16
, pp. 707-711
-
-
Boulter, J.M.1
Glick, M.2
Todorov, P.T.3
Baston, E.4
Sami, M.5
Rizkallah, P.6
Jakobsen, B.K.7
-
117
-
-
0026567963
-
Formation of a bispecific antibody by the use of leucine zippers
-
1531669
-
Kostelny SA, Cole MS, Tso JY. Formation of a bispecific antibody by the use of leucine zippers. J Immunol 1992; 148:1547-53; PMID:1531669
-
(1992)
J Immunol
, vol.148
, pp. 1547-1553
-
-
Kostelny, S.A.1
Cole, M.S.2
Tso, J.Y.3
-
118
-
-
0030009282
-
Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library
-
8631798
-
De Kruif J, Logtenberg T. Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library. J Biol Chem 1996; 271:7630-34; PMID:8631798
-
(1996)
J Biol Chem
, vol.271
, pp. 7630-7634
-
-
De Kruif, J.1
Logtenberg, T.2
-
119
-
-
0030738617
-
New protein engineering approaches to multivalent and bispecific antibody fragments
-
9237094
-
Plückthun A, Pack P. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 1997; 3:83-105; PMID:9237094
-
(1997)
Immunotechnology
, vol.3
, pp. 83-105
-
-
Plückthun, A.1
Pack, P.2
-
120
-
-
0038867807
-
A dimeric bispecific miniantibody combines two specificities with avidity
-
9710248
-
Müller KM, Arndt KM, Plückthun A. A dimeric bispecific miniantibody combines two specificities with avidity. FEBS Lett 1998; 432:45-49; PMID:9710248
-
(1998)
FEBS Lett
, vol.432
, pp. 45-49
-
-
Müller, K.M.1
Arndt, K.M.2
Plückthun, A.3
-
121
-
-
0032579437
-
The first constant domain (C(H)1 and C(L)) of an antibody used as heterodimerization domain for bispecific miniantibodies
-
9490020
-
Müller KM, Arndt KM, Strittmatter W, Plückthun A. The first constant domain (C(H)1 and C(L)) of an antibody used as heterodimerization domain for bispecific miniantibodies. FEBS Lett 1998; 422:259-264; PMID:9490020
-
(1998)
FEBS Lett
, vol.422
, pp. 259-264
-
-
Müller, K.M.1
Arndt, K.M.2
Strittmatter, W.3
Plückthun, A.4
-
122
-
-
84882241230
-
Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells
-
23757164
-
Rozan C, Cornillon A, Pétiard C, Chartier M, Behar G, Boix C, Kerfelec B, Robert B, Pèlegrin A, Chames P, et al. Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells. Mol Cancer Ther 2013; 12:1481-91; PMID:23757164; http://dx.doi.org/10.1158/1535-7163.MCT-12-1012
-
(2013)
Mol Cancer Ther
, vol.12
, pp. 1481-1491
-
-
Rozan, C.1
Cornillon, A.2
Pétiard, C.3
Chartier, M.4
Behar, G.5
Boix, C.6
Kerfelec, B.7
Robert, B.8
Pèlegrin, A.9
Chames, P.10
-
123
-
-
84978648964
-
Overcoming the Constraints of Anti-HIV/CD89 Bispecific Antibodies That Limit Viral Inhibition
-
27419146
-
Yu X, Duval M, Gawron M, Posner MR, Cavacini LA. Overcoming the Constraints of Anti-HIV/CD89 Bispecific Antibodies That Limit Viral Inhibition. J Immunol Res 2016; 2016:9425172; PMID:27419146; http://dx.doi.org/10.1155/2016/9425172
-
(2016)
J Immunol Res
, vol.2016
, pp. 9425172
-
-
Yu, X.1
Duval, M.2
Gawron, M.3
Posner, M.R.4
Cavacini, L.A.5
-
124
-
-
33646477258
-
Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting
-
16636283
-
Rossi EA, Goldenberg DM, Cardillo TM, McBridge WJ, Skarkey RM, Chang CH. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci USA 2006; 103:68416846; PMID:16636283; http://dx.doi.org/10.1073/pnas.0600982103
-
(2006)
Proc Natl Acad Sci USA
, vol.103
, pp. 68416846
-
-
Rossi, E.A.1
Goldenberg, D.M.2
Cardillo, T.M.3
McBridge, W.J.4
Skarkey, R.M.5
Chang, C.H.6
-
125
-
-
48549083845
-
Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody
-
18593929
-
Sharkey RM, Karacay H, Litwin S, Rossi EA, McBridge WJ, Chang CH, Goldenberg DM. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res 2008; 68:5282-90; PMID:18593929; http://dx.doi.org/10.1158/0008-5472.CAN-08-0037
-
(2008)
Cancer Res
, vol.68
, pp. 5282-5290
-
-
Sharkey, R.M.1
Karacay, H.2
Litwin, S.3
Rossi, E.A.4
McBridge, W.J.5
Chang, C.H.6
Goldenberg, D.M.7
-
126
-
-
84865212772
-
Complex and defined biostructures with the dock-and-lock method
-
22739259
-
Rossi EA, Goldenberg DM, Chang CH. Complex and defined biostructures with the dock-and-lock method. Trends Pharmacol Sci 2012; 33:474-81; PMID:22739259; http://dx.doi.org/10.1016/j.tips.2012.06.001
-
(2012)
Trends Pharmacol Sci
, vol.33
, pp. 474-481
-
-
Rossi, E.A.1
Goldenberg, D.M.2
Chang, C.H.3
-
127
-
-
77949883007
-
Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy
-
20350628
-
Sharkey RM, Rossi EA, McBridge WJ, Chang CH, Goldenberg DM. Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Semin Nucl Med 2010; 40:190-203; PMID:20350628; http://dx.doi.org/10.1053/j.semnuclmed.2009.12.002
-
(2010)
Semin Nucl Med
, vol.40
, pp. 190-203
-
-
Sharkey, R.M.1
Rossi, E.A.2
McBridge, W.J.3
Chang, C.H.4
Goldenberg, D.M.5
-
128
-
-
85047686965
-
A new class of bispecific antibodies to redirect T cells for cancer immunotherapy
-
24492297
-
Rossi DL, Rossi EA, Cardillo TM, Goldenberg DM, Chang CH. A new class of bispecific antibodies to redirect T cells for cancer immunotherapy. Mabs 2014; 6:381-91; PMID:24492297; http://dx.doi.org/10.4161/mabs.27385
-
(2014)
Mabs
, vol.6
, pp. 381-391
-
-
Rossi, D.L.1
Rossi, E.A.2
Cardillo, T.M.3
Goldenberg, D.M.4
Chang, C.H.5
-
129
-
-
0347384086
-
Design of mutlivalent complexes using the barnase*barstar module
-
14634668
-
Deyev SM, Waibel R, Lebedenko EN, Schubiger AP, Plückthun A. Design of mutlivalent complexes using the barnase*barstar module. Nat Biotechnol 2003; 21:1486-92; PMID:14634668; http://dx.doi.org/10.1038/nbt916
-
(2003)
Nat Biotechnol
, vol.21
, pp. 1486-1492
-
-
Deyev, S.M.1
Waibel, R.2
Lebedenko, E.N.3
Schubiger, A.P.4
Plückthun, A.5
-
130
-
-
33845611043
-
Expression of single-chain antibody-barstar fusion in plants
-
16938381
-
Semenyuk EG, Stremovskiy OA, Edelweiss EF, Shirshikova OV, Balandin TG, Buryanov YI, Deyev SM. Expression of single-chain antibody-barstar fusion in plants. Biochimie 2007; 89:31-8; PMID:16938381
-
(2007)
Biochimie
, vol.89
, pp. 31-38
-
-
Semenyuk, E.G.1
Stremovskiy, O.A.2
Edelweiss, E.F.3
Shirshikova, O.V.4
Balandin, T.G.5
Buryanov, Y.I.6
Deyev, S.M.7
-
131
-
-
84872559106
-
Optimization of multivalent bispecific antibodies and immunocytokines with improved in vivo properties
-
23116517
-
Rossi EA, Chang CH, Cardillo TM, Goldenberg DM. Optimization of multivalent bispecific antibodies and immunocytokines with improved in vivo properties. Bioconjug Chem 2012; 24:63-71; PMID:23116517; http://dx.doi.org/10.1021/bc300488f
-
(2012)
Bioconjug Chem
, vol.24
, pp. 63-71
-
-
Rossi, E.A.1
Chang, C.H.2
Cardillo, T.M.3
Goldenberg, D.M.4
-
132
-
-
84885370061
-
Albumin as a versatile platform for drug half-life extension
-
23639804
-
Sleep D, Cameron J, Evans LR. Albumin as a versatile platform for drug half-life extension. Biochim Biophys Acta 2013; 1830:526-5534; PMID:23639804; http://dx.doi.org/10.1016/j.bbagen.2013.04.023
-
(2013)
Biochim Biophys Acta
, vol.1830
, pp. 526-5534
-
-
Sleep, D.1
Cameron, J.2
Evans, L.R.3
-
133
-
-
34250361507
-
Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin
-
17347147
-
Müller D, Karle A, Meissburger B, Höfig I, Stork R, Kontermann RE. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem 2007; 282:12650-60; PMID:17347147; http://dx.doi.org/10.1074/jbc.M700820200
-
(2007)
J Biol Chem
, vol.282
, pp. 12650-12660
-
-
Müller, D.1
Karle, A.2
Meissburger, B.3
Höfig, I.4
Stork, R.5
Kontermann, R.E.6
-
134
-
-
84859409756
-
Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3
-
22248472
-
McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther 2012; 11:582-93; PMID:22248472; http://dx.doi.org/10.1158/1535-7163.MCT-11-0820
-
(2012)
Mol Cancer Ther
, vol.11
, pp. 582-593
-
-
McDonagh, C.F.1
Huhalov, A.2
Harms, B.D.3
Adams, S.4
Paragas, V.5
Oyama, S.6
Zhang, B.7
Luus, L.8
Overland, R.9
Nguyen, S.10
-
135
-
-
18844444471
-
A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma
-
15897589
-
Vallera DA, Todhunter DA, Kuroki DW, Shu Y, Sicheneder A, Chen H. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma. Clin Cancer Res 2005; 11:3879-88; PMID:15897589; http://dx.doi.org/10.1158/1078-0432.CCR-04-2290
-
(2005)
Clin Cancer Res
, vol.11
, pp. 3879-3888
-
-
Vallera, D.A.1
Todhunter, D.A.2
Kuroki, D.W.3
Shu, Y.4
Sicheneder, A.5
Chen, H.6
-
136
-
-
33750608847
-
Fusion of chemotactic peptide to a single-chain bi-specific antibody (scBsAb) potentiates its cytotoxicity to target tumour cells
-
16836487
-
Song J, Wang X, Lei C, Piao J, Yin C, Zhang Z, Lin Q, Huang H. Fusion of chemotactic peptide to a single-chain bi-specific antibody (scBsAb) potentiates its cytotoxicity to target tumour cells. Biotechnol Appl Biochem 2006; 45:147-54; PMID:16836487; http://dx.doi.org/10.1042/BA20060060
-
(2006)
Biotechnol Appl Biochem
, vol.45
, pp. 147-154
-
-
Song, J.1
Wang, X.2
Lei, C.3
Piao, J.4
Yin, C.5
Zhang, Z.6
Lin, Q.7
Huang, H.8
-
137
-
-
0029841188
-
Symmetry of Fv architecture is conducive to grafting a second antibody binding site in the Fv region
-
8889174
-
Keck PC, Huston JS. Symmetry of Fv architecture is conducive to grafting a second antibody binding site in the Fv region. Biophys J 1996; 71:2002-11; PMID:8889174; http://dx.doi.org/10.1016/S0006-3495(96)79398-0
-
(1996)
Biophys J
, vol.71
, pp. 2002-2011
-
-
Keck, P.C.1
Huston, J.S.2
-
138
-
-
84957708807
-
Engineered IgG1-Fc - one fragment to bind them all
-
26864108
-
Lobner E, Traxlmayr MW, Obinger C, Hasenhindl C. Engineered IgG1-Fc - one fragment to bind them all. Immunol Rev 2016; 270:113-31; PMID:26864108; http://dx.doi.org/10.1111/imr.12385
-
(2016)
Immunol Rev
, vol.270
, pp. 113-131
-
-
Lobner, E.1
Traxlmayr, M.W.2
Obinger, C.3
Hasenhindl, C.4
-
139
-
-
0022555989
-
Bispecific monoclonal antibodies from hybrid hybridoma
-
3724461
-
Suresh MR, Cuello AC, Milstein C. Bispecific monoclonal antibodies from hybrid hybridoma. Methods Enzymol 1986; 121:210-28; PMID:3724461
-
(1986)
Methods Enzymol
, vol.121
, pp. 210-228
-
-
Suresh, M.R.1
Cuello, A.C.2
Milstein, C.3
-
140
-
-
77953665930
-
Structural and functional characterization of the trifunctional antibody catumaxomab
-
20418662
-
Chelius D, Ruf P, Gruber P, Plöscher M, Liedtke R, Gansberger E, Hess J, Wasiliu M, Lindhofer H. Structural and functional characterization of the trifunctional antibody catumaxomab. MAbs 2010; 2:309-19; PMID:20418662
-
(2010)
MAbs
, vol.2
, pp. 309-319
-
-
Chelius, D.1
Ruf, P.2
Gruber, P.3
Plöscher, M.4
Liedtke, R.5
Gansberger, E.6
Hess, J.7
Wasiliu, M.8
Lindhofer, H.9
-
141
-
-
0029063312
-
Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies
-
7602098
-
Lindhofer H, Mocikat R, Steipe B, Thierfelder S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 1995; 155:219-25; PMID:7602098
-
(1995)
J Immunol
, vol.155
, pp. 219-225
-
-
Lindhofer, H.1
Mocikat, R.2
Steipe, B.3
Thierfelder, S.4
-
142
-
-
0032581013
-
Contribution of domain interface residues to the stability of antibody CH3 domain homodimers
-
9649307
-
Dall'Acqua W, Simon AL, Mulkerrin MG, Carter P. Contribution of domain interface residues to the stability of antibody CH3 domain homodimers. Biochemistry 1998; 37:9266-73; PMID:9649307; http://dx.doi.org/10.1021/bi980270i
-
(1998)
Biochemistry
, vol.37
, pp. 9266-9273
-
-
Dall'Acqua, W.1
Simon, A.L.2
Mulkerrin, M.G.3
Carter, P.4
-
143
-
-
0029946383
-
'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization
-
8844834
-
Ridgway JB, Presta LG, Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9:617-21; PMID:8844834
-
(1996)
Protein Eng
, vol.9
, pp. 617-621
-
-
Ridgway, J.B.1
Presta, L.G.2
Carter, P.3
-
144
-
-
84892598423
-
Superior antitumor activity of a novel bispecific antibody cotargeting human epidermal growth factor receptor 2 and type I insulin-like growth factor receptor
-
24227890
-
Chen C, Zhang Y, Zhang Y, Li J, Tsao SW, Zhang MY. Superior antitumor activity of a novel bispecific antibody cotargeting human epidermal growth factor receptor 2 and type I insulin-like growth factor receptor. Mol Cancer Ther 2013; 13:90-100; PMID:24227890; http://dx.doi.org/10.1158/1535-7163.MCT-13-0558
-
(2013)
Mol Cancer Ther
, vol.13
, pp. 90-100
-
-
Chen, C.1
Zhang, Y.2
Zhang, Y.3
Li, J.4
Tsao, S.W.5
Zhang, M.Y.6
-
145
-
-
0031552589
-
Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library
-
9231898
-
Atwell S, Ridgway JB, Wells JA, Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol 1997; 270:26-35; PMID:9231898; http://dx.doi.org/10.1006/jmbi.1997.1116
-
(1997)
J Mol Biol
, vol.270
, pp. 26-35
-
-
Atwell, S.1
Ridgway, J.B.2
Wells, J.A.3
Carter, P.4
-
146
-
-
0031876578
-
An efficient route to human bispecific IgG
-
9661204
-
Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. An efficient route to human bispecific IgG. Nat Biotechnol 1998; 16:677-681; PMID:9661204; http://dx.doi.org/10.1038/nbt0798-677
-
(1998)
Nat Biotechnol
, vol.16
, pp. 677-681
-
-
Merchant, A.M.1
Zhu, Z.2
Yuan, J.Q.3
Goddard, A.4
Adams, C.W.5
Presta, L.G.6
Carter, P.7
-
147
-
-
84889850198
-
Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity
-
23995614
-
Shatz W, Chung S, Li B, Marshall B, Tejada M, Phung W, Sandoval W, Kelley RF, Scheer JM. Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity. MAbs 2013; 5:872-81; PMID:23995614; http://dx.doi.org/10.4161/mabs.26307
-
(2013)
MAbs
, vol.5
, pp. 872-881
-
-
Shatz, W.1
Chung, S.2
Li, B.3
Marshall, B.4
Tejada, M.5
Phung, W.6
Sandoval, W.7
Kelley, R.F.8
Scheer, J.M.9
-
148
-
-
84874562364
-
dentification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity
-
23468998
-
Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C, Wakabayashi T, Tanaka E, Muto A, Kojima T, Kitazawa T, et al. dentification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One 2013; 8:e57479; PMID:23468998; http://dx.doi.org/10.1371/journal.pone.0057479
-
(2013)
PLoS One
, vol.8
, pp. e57479
-
-
Sampei, Z.1
Igawa, T.2
Soeda, T.3
Okuyama-Nishida, Y.4
Moriyama, C.5
Wakabayashi, T.6
Tanaka, E.7
Muto, A.8
Kojima, T.9
Kitazawa, T.10
-
149
-
-
84881460836
-
Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies
-
23831709
-
Spiess C, Merchant M, Huang A, Zheng Z, Yang NY, Peng J, Ellerman D, Shatz W, Reilly D, Yansura DG, et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat Biotechnol 2013; 31:753-8; PMID:23831709; http://dx.doi.org/10.1038/nbt.2621
-
(2013)
Nat Biotechnol
, vol.31
, pp. 753-758
-
-
Spiess, C.1
Merchant, M.2
Huang, A.3
Zheng, Z.4
Yang, N.Y.5
Peng, J.6
Ellerman, D.7
Shatz, W.8
Reilly, D.9
Yansura, D.G.10
-
150
-
-
84907494587
-
-
25228655
-
Juntilla TT, Li J, Johnston J, Hristopoulos M, Clark R, Ellerman D, Wang BE, Li Y, Mathieu M, Li G, et al. Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells. 2014; 74:5561-71; PMID:25228655; http://dx.doi.org/10.1158/0008-5472.CAN-13-3622-T
-
(2014)
Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells
, vol.74
, pp. 5561-5571
-
-
Juntilla, T.T.1
Li, J.2
Johnston, J.3
Hristopoulos, M.4
Clark, R.5
Ellerman, D.6
Wang, B.E.7
Li, Y.8
Mathieu, M.9
Li, G.10
-
151
-
-
84946811219
-
Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells
-
26413868
-
Sun JA, Pickeral J, Liu L, Stanfield-Oakley SA, Lam CY, Garrido C, Pollara J, LaBranche C, Bonsignori M, Moody MA, et al. Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. J Clin Invest 2015; PMID:26413868; http://dx.doi.org/10.1172/JCI82314125:4077-4090
-
(2015)
J Clin Invest
-
-
Sun, J.A.1
Pickeral, J.2
Liu, L.3
Stanfield-Oakley, S.A.4
Lam, C.Y.5
Garrido, C.6
Pollara, J.7
LaBranche, C.8
Bonsignori, M.9
Moody, M.A.10
-
152
-
-
11144238604
-
Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format
-
15471859
-
Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem 2004; 279:53907-14; PMID:15471859; http://dx.doi.org/10.1074/jbc.M407888200
-
(2004)
J Biol Chem
, vol.279
, pp. 53907-53914
-
-
Shahied, L.S.1
Tang, Y.2
Alpaugh, R.K.3
Somer, R.4
Greenspon, D.5
Weiner, L.M.6
-
153
-
-
77954225154
-
Development of two-part strategies to identify a therapeutic bispecific antibody that inhibits IgE receptor signaling
-
20444694
-
Jackman J, Chen Y, Huang A, Moffat B, Scheer JM, Leong SR, Lee WP, Zhang J, Sharma N, Lu Y, et al. Development of two-part strategies to identify a therapeutic bispecific antibody that inhibits IgE receptor signaling. J Biol Chem 2010; 285:20850-9; PMID:20444694; http://dx.doi.org/10.1074/jbc.M110.113910
-
(2010)
J Biol Chem
, vol.285
, pp. 20850-20859
-
-
Jackman, J.1
Chen, Y.2
Huang, A.3
Moffat, B.4
Scheer, J.M.5
Leong, S.R.6
Lee, W.P.7
Zhang, J.8
Sharma, N.9
Lu, Y.10
-
154
-
-
84884194586
-
Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines
-
23880771
-
Spiess C, Bevers J, 3rd, Jackman J, Chiang N, Nakamura G, Dillon M, Liu H, Molina P, Elliott JM, Shatz W, et al. Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines. J Biol Chem 2013; 288:26583-93; PMID:23880771; http://dx.doi.org/10.1074/jbc.M113.480483
-
(2013)
J Biol Chem
, vol.288
, pp. 26583-26593
-
-
Spiess, C.1
Bevers, J.2
Jackman, J.3
Chiang, N.4
Nakamura, G.5
Dillon, M.6
Liu, H.7
Molina, P.8
Elliott, J.M.9
Shatz, W.10
-
155
-
-
12944312223
-
A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis
-
15680154
-
Xie Z, Guo N, Yu M, Hu M, Shen B. A new format of bispecific antibody:highly efficient heterodimerization, expression and tumor cell lysis. J Immunol Methods 2005; 296:96-101; PMID:15680154; http://dx.doi.org/10.1016/j.jim.2004.11.005
-
(2005)
J Immunol Methods
, vol.296
, pp. 96-101
-
-
Xie, Z.1
Guo, N.2
Yu, M.3
Hu, M.4
Shen, B.5
-
156
-
-
80054765331
-
A two-in-one antibody against HER3 and EGFR has superor inhibitory activity compared with monospecific antibodies
-
22014573
-
Schaefer G, Haber L, Crocker LM, Shia S, Shao L, dowbenko D, Totpal K, Wong A, Lee CV, Stawicki S, et al. A two-in-one antibody against HER3 and EGFR has superor inhibitory activity compared with monospecific antibodies. Cancer Cell 2011; 20:472-86; PMID:22014573; http://dx.doi.org/10.1016/j.ccr.2011.09.003
-
(2011)
Cancer Cell
, vol.20
, pp. 472-486
-
-
Schaefer, G.1
Haber, L.2
Crocker, L.M.3
Shia, S.4
Shao, L.5
dowbenko, D.6
Totpal, K.7
Wong, A.8
Lee, C.V.9
Stawicki, S.10
-
157
-
-
84866993578
-
Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties
-
Castoldi R, Jucknischke U, Pradel LP, Arnold E, Klein C, Scheiblich S. Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties. Protein Eng Des Sel 2012; 25:551-9
-
(2012)
Protein Eng Des Sel
, vol.25
, pp. 551-559
-
-
Castoldi, R.1
Jucknischke, U.2
Pradel, L.P.3
Arnold, E.4
Klein, C.5
Scheiblich, S.6
-
158
-
-
84866980918
-
Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing
-
22976197
-
Metz S, Panke C, Haas AK, Schanzer J, Lau W, Croasdale R, Hoffmann E, Schneider B, Auer J, Gassner C, et al. Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing. Protein Eng Des Sel 2012; 25:571-80; PMID:22976197; http://dx.doi.org/10.1093/protein/gzs064
-
(2012)
Protein Eng Des Sel
, vol.25
, pp. 571-580
-
-
Metz, S.1
Panke, C.2
Haas, A.K.3
Schanzer, J.4
Lau, W.5
Croasdale, R.6
Hoffmann, E.7
Schneider, B.8
Auer, J.9
Gassner, C.10
-
159
-
-
84881405670
-
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
-
23882082
-
Merchant M, Ma X, Maun HR, Zheng Z, Peng J, Romero M, Huang A, Yang NY, Nishimura M, Greve J, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci USA 2013; 110:E2987-2996; PMID:23882082; http://dx.doi.org/10.1073/pnas.1302725110
-
(2013)
Proc Natl Acad Sci USA
, vol.110
, pp. E2987-E2996
-
-
Merchant, M.1
Ma, X.2
Maun, H.R.3
Zheng, Z.4
Peng, J.5
Romero, M.6
Huang, A.7
Yang, N.Y.8
Nishimura, M.9
Greve, J.10
-
160
-
-
84903843654
-
A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties
-
24841203
-
Schanzer JM, Wartha K, Croasdale R, Moser S, Künkele KP, Ries C, Scheuer W, Duerr H, Pompiati S, Pollman J, et al. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties. J Biol Chem 2014; 289:18693-796; PMID:24841203; http://dx.doi.org/10.1074/jbc.M113.528109
-
(2014)
J Biol Chem
, vol.289
, pp. 18693-18796
-
-
Schanzer, J.M.1
Wartha, K.2
Croasdale, R.3
Moser, S.4
Künkele, K.P.5
Ries, C.6
Scheuer, W.7
Duerr, H.8
Pompiati, S.9
Pollman, J.10
-
161
-
-
84921355021
-
Production of bispecific antibodies in “knobs-into-holes” using a cell-free expression system
-
25427258
-
Xu Y, Lee J, Tran C, Heibeck TH, Wang WD, Yang J, Stafford RL, Steiner AR, Sato AK, Hallam TJ, et al. Production of bispecific antibodies in “knobs-into-holes” using a cell-free expression system. MAbs 2015; 7:231-42; PMID:25427258; http://dx.doi.org/10.4161/19420862.2015.989013
-
(2015)
MAbs
, vol.7
, pp. 231-242
-
-
Xu, Y.1
Lee, J.2
Tran, C.3
Heibeck, T.H.4
Wang, W.D.5
Yang, J.6
Stafford, R.L.7
Steiner, A.R.8
Sato, A.K.9
Hallam, T.J.10
-
162
-
-
84921395881
-
Nanocell targeting using engineered bispecific antibodies
-
25523746
-
Taylor K, Howard CB, Jones ML, Sedliarou I, MacDiarmid J, Brahmbhatt H, Munro TP, Mahler SM. Nanocell targeting using engineered bispecific antibodies. MAbs 2015; 7:53-65; PMID:25523746; http://dx.doi.org/10.4161/19420862.2014.985952
-
(2015)
MAbs
, vol.7
, pp. 53-65
-
-
Taylor, K.1
Howard, C.B.2
Jones, M.L.3
Sedliarou, I.4
MacDiarmid, J.5
Brahmbhatt, H.6
Munro, T.P.7
Mahler, S.M.8
-
163
-
-
81255210896
-
A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens
-
22123055
-
Moore GL, Bautista C, Pong E, Nguyen DH, Jacinto J, Eivaci A, Muchhal US, Karki S, Chu SY, Lazar GA. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. MAbs 2011; 3:546-557; PMID:22123055; http://dx.doi.org/10.4161/mabs.3.6.18123
-
(2011)
MAbs
, vol.3
, pp. 546-557
-
-
Moore, G.L.1
Bautista, C.2
Pong, E.3
Nguyen, D.H.4
Jacinto, J.5
Eivaci, A.6
Muchhal, U.S.7
Karki, S.8
Chu, S.Y.9
Lazar, G.A.10
-
164
-
-
84883876685
-
Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design
-
23924797
-
Von Kreudenstein TS, Escobar-Carbrera E, lario PI, D'Angelo I, Brault K, Kelly J, Durocher Y, Baardsnes J, Woods RJ, Xie MH, et al. Improving biophysical properties of a bispecific antibody scaffold to aid developability:quality by molecular design. MAbs 2013; 5:646-54; PMID:23924797; http://dx.doi.org/10.4161/mabs.25632
-
(2013)
MAbs
, vol.5
, pp. 646-654
-
-
Von Kreudenstein, T.S.1
Escobar-Carbrera, E.2
lario, P.I.3
D'Angelo, I.4
Brault, K.5
Kelly, J.6
Durocher, Y.7
Baardsnes, J.8
Woods, R.J.9
Xie, M.H.10
-
165
-
-
84883869187
-
LC-MS characterization and purity assessment of a prototype bispecific antibody
-
23884083
-
Woods RJ, Xie MH, von Kreudenstein TS, Ng GY, Dixit SB. LC-MS characterization and purity assessment of a prototype bispecific antibody. MAbs 2013; 5:711-22; PMID:23884083; http://dx.doi.org/10.4161/mabs.25488
-
(2013)
MAbs
, vol.5
, pp. 711-722
-
-
Woods, R.J.1
Xie, M.H.2
von Kreudenstein, T.S.3
Ng, G.Y.4
Dixit, S.B.5
-
166
-
-
77953485268
-
Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG
-
20400508
-
Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, Ng SB, Born T, Retter M, Manchulenko K, et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects:applications to bispecific molecules and monovalent IgG. J Biol Chem 2010; 285:19637-46; PMID:20400508; http://dx.doi.org/10.1074/jbc.M110.117382
-
(2010)
J Biol Chem
, vol.285
, pp. 19637-19646
-
-
Gunasekaran, K.1
Pentony, M.2
Shen, M.3
Garrett, L.4
Forte, C.5
Woodward, A.6
Ng, S.B.7
Born, T.8
Retter, M.9
Manchulenko, K.10
-
167
-
-
84925321830
-
A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism
-
25583986
-
Liu Z, Leng EC, Gunasekaran K, Pentony M, Shen M, Howard M, Stoops J, Manchulenko K, Razinkov V, Liu H, et al. A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism. J Biol Chem 2015; 290:7535-62; PMID:25583986; http://dx.doi.org/10.1074/jbc.M114.620260
-
(2015)
J Biol Chem
, vol.290
, pp. 7535-7562
-
-
Liu, Z.1
Leng, E.C.2
Gunasekaran, K.3
Pentony, M.4
Shen, M.5
Howard, M.6
Stoops, J.7
Manchulenko, K.8
Razinkov, V.9
Liu, H.10
-
168
-
-
84971221594
-
A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair
-
27230681
-
Florio M, Guaneskaran K, Stolina M, Liu L, Tipton B, Salimi-Moosavi H, Asuncion FJ, Li C, Sun B, Tan HL, et al. A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. Nat Commun 2016; 7:11505; PMID:27230681; http://dx.doi.org/10.1038/ncomms11505
-
(2016)
Nat Commun
, vol.7
, pp. 11505
-
-
Florio, M.1
Guaneskaran, K.2
Stolina, M.3
Liu, L.4
Tipton, B.5
Salimi-Moosavi, H.6
Asuncion, F.J.7
Li, C.8
Sun, B.9
Tan, H.L.10
-
169
-
-
84942002424
-
Preclinical activity of MCLA-128, an ADCC enhanced human bispecific IgG1 antibody targeting the HER2:HER3 heterodimer
-
Geuijen C, Rovers E, Nijhuis R, Visser T, den Blanken-Smit R, Barelink W, et al. Preclinical activity of MCLA-128, an ADCC enhanced human bispecific IgG1 antibody targeting the HER2:HER3 heterodimer. Journal of Clinical Oncology 2014; 32:suppl:560
-
(2014)
Journal of Clinical Oncology
, vol.32
, pp. 560
-
-
Geuijen, C.1
Rovers, E.2
Nijhuis, R.3
Visser, T.4
den Blanken-Smit, R.5
Barelink, W.6
-
170
-
-
84862015979
-
Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair
-
22543237
-
Strop P, Ho WH, Boustany LM, Abdiche YN, Lindquist KC, Farias SE, Rickert M, Appah CT, Pascua E, Radcliffe T, et al. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J Mol Biol 2012; 420:204-19; PMID:22543237; http://dx.doi.org/10.1016/j.jmb.2012.04.020
-
(2012)
J Mol Biol
, vol.420
, pp. 204-219
-
-
Strop, P.1
Ho, W.H.2
Boustany, L.M.3
Abdiche, Y.N.4
Lindquist, K.C.5
Farias, S.E.6
Rickert, M.7
Appah, C.T.8
Pascua, E.9
Radcliffe, T.10
-
171
-
-
84890464536
-
A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity
-
24132142
-
Choi HJ, Kim YJ, Lee S, Kim YS. A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity. Mol Cancer Ther 2013; 12:2748-59; PMID:24132142; http://dx.doi.org/10.1158/1535-7163.MCT-13-0628
-
(2013)
Mol Cancer Ther
, vol.12
, pp. 2748-2759
-
-
Choi, H.J.1
Kim, Y.J.2
Lee, S.3
Kim, Y.S.4
-
172
-
-
84923930637
-
Crystal structures of immunoglobulin Fc heterodimers reveal the molecular basis for heterodimer formation
-
25743157
-
Choi HJ, Seok SH, Kim YJ, Seo Md, Kim YS. Crystal structures of immunoglobulin Fc heterodimers reveal the molecular basis for heterodimer formation. Mol Immunol 2015; 65:377-83; PMID:25743157; http://dx.doi.org/10.1016/j.molimm.2015.02.017
-
(2015)
Mol Immunol
, vol.65
, pp. 377-383
-
-
Choi, H.J.1
Seok, S.H.2
Kim, Y.J.3
Seo, M.4
Kim, Y.S.5
-
173
-
-
84956612008
-
Engineering of Immunoglobulin Fc Heterodimers Using Yeast Surface-Displayed Combinatorial Fc Library Screening
-
26675656
-
Choi HJ, Kim YJ, Choi DK, Kim YS. Engineering of Immunoglobulin Fc Heterodimers Using Yeast Surface-Displayed Combinatorial Fc Library Screening. PLoS One 2015; 10:e0145349; PMID:26675656
-
(2015)
PLoS One
, vol.10
, pp. e0145349
-
-
Choi, H.J.1
Kim, Y.J.2
Choi, D.K.3
Kim, Y.S.4
-
174
-
-
34548694517
-
Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange
-
17872445
-
van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martinez-Martinze P, Vermeulen E, den Bleker TH, Wiegman L, Vink T, Aarden LA, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007; 317:1554-7; PMID:17872445; http://dx.doi.org/10.1126/science.1144603
-
(2007)
Science
, vol.317
, pp. 1554-1557
-
-
van der Neut Kolfschoten, M.1
Schuurman, J.2
Losen, M.3
Bleeker, W.K.4
Martinez-Martinze, P.5
Vermeulen, E.6
den Bleker, T.H.7
Wiegman, L.8
Vink, T.9
Aarden, L.A.10
-
175
-
-
84875542050
-
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
-
23479652
-
Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci USA 2013; 110:5145-50; PMID:23479652; http://dx.doi.org/10.1073/pnas.1220145110
-
(2013)
Proc Natl Acad Sci USA
, vol.110
, pp. 5145-5150
-
-
Labrijn, A.F.1
Meesters, J.I.2
de Goeij, B.E.3
van den Bremer, E.T.4
Neijssen, J.5
van Kampen, M.D.6
Strumane, K.7
Verploegen, S.8
Kundu, A.9
Gramer, M.J.10
-
176
-
-
84963959117
-
Controlled Fab-arm exchange for the generation of stable bispecific IgG1
-
25255089
-
Labrijn AF, Meesters JI, Priem P, de Jong RN, van den Bremer ET, van Kampen MD, Gerritsen AF, Schuurman J, Parren PW. Controlled Fab-arm exchange for the generation of stable bispecific IgG1. Nat Protoc 2014; 9:2450-63; PMID:25255089; http://dx.doi.org/10.1038/nprot.2014.169
-
(2014)
Nat Protoc
, vol.9
, pp. 2450-2463
-
-
Labrijn, A.F.1
Meesters, J.I.2
Priem, P.3
de Jong, R.N.4
van den Bremer, E.T.5
van Kampen, M.D.6
Gerritsen, A.F.7
Schuurman, J.8
Parren, P.W.9
-
177
-
-
84889831910
-
Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches
-
23995617
-
Gramer MJ, van den Bremer ET, van Kampen MD, Kundu A, Kopfmann P, Etter E, Stinehelfer D, Long J, Lannom T, Noordergraaf EH, et al. Production of stable bispecific IgG1 by controlled Fab-arm exchange:scalability from bench to large-scale manufacturing by application of standard approaches. MAbs 2013, 5:962-73; PMID:23995617; http://dx.doi.org/10.4161/mabs.26233
-
(2013)
MAbs
, vol.5
, pp. 962-973
-
-
Gramer, M.J.1
van den Bremer, E.T.2
van Kampen, M.D.3
Kundu, A.4
Kopfmann, P.5
Etter, E.6
Stinehelfer, D.7
Long, J.8
Lannom, T.9
Noordergraaf, E.H.10
-
178
-
-
77954628740
-
SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies
-
20299542
-
Davis JH, Aperlo C, Kurosawa E, Lan Y, Lo KM, Huston JS. SEEDbodies:fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel 2010; 23:195-202; PMID:20299542; http://dx.doi.org/10.1093/protein/gzp094
-
(2010)
Protein Eng Des Sel
, vol.23
, pp. 195-202
-
-
Davis, J.H.1
Aperlo, C.2
Kurosawa, E.3
Lan, Y.4
Lo, K.M.5
Huston, J.S.6
-
179
-
-
79955440692
-
Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies
-
21498564
-
Muda M, Gross AW, Dawson JP, He C, Kurosawa E, Scheickhardt R, Dugas M, Soloviev M, Bernhardt A, Fischer D, et al. Therapeutic assessment of SEED:a new engineered antibody platform designed to generate mono- and bispecific antibodies. Protein Eng Des Sel 2011; 24:447-54; PMID:21498564; http://dx.doi.org/10.1093/protein/gzq123
-
(2011)
Protein Eng Des Sel
, vol.24
, pp. 447-454
-
-
Muda, M.1
Gross, A.W.2
Dawson, J.P.3
He, C.4
Kurosawa, E.5
Scheickhardt, R.6
Dugas, M.7
Soloviev, M.8
Bernhardt, A.9
Fischer, D.10
-
180
-
-
84865691154
-
Anti-EGFR biparatopic-SEED antibody has enhanced combination-activity in a single molecule
-
22426455
-
Kelton C, Wesolowski JS, Soloviev M, Schweickhardt R, Fischer D, Kurosawa E, McKenna SD, Gross AW. Anti-EGFR biparatopic-SEED antibody has enhanced combination-activity in a single molecule. Arch Biochem Biophys 2012; 526:219-25; PMID:22426455; http://dx.doi.org/10.1016/j.abb.2012.03.005
-
(2012)
Arch Biochem Biophys
, vol.526
, pp. 219-225
-
-
Kelton, C.1
Wesolowski, J.S.2
Soloviev, M.3
Schweickhardt, R.4
Fischer, D.5
Kurosawa, E.6
McKenna, S.D.7
Gross, A.W.8
-
181
-
-
85011386889
-
BEAT the bispecific challenge: a novel and efficient platform for the expression of bispecific IgGs
-
Moretti P, Skegro D, Ollier R, Wassmann P, Aebischer C, Laurent T, et al. BEAT the bispecific challenge:a novel and efficient platform for the expression of bispecific IgGs. BMC Proceedings 2013; 7(Suppl 6):O9
-
(2013)
BMC Proceedings
, vol.7
, pp. O9
-
-
Moretti, P.1
Skegro, D.2
Ollier, R.3
Wassmann, P.4
Aebischer, C.5
Laurent, T.6
-
182
-
-
85011372526
-
GBR1302: a BEAT bispecific antibody for the treatment of HER2 positive cancers
-
Croset A, Macoin J, Ollier R, Pluess M, Delon C, Skegro D, et al. GBR1302:a BEAT bispecific antibody for the treatment of HER2 positive cancers. Eur J Cancer 2014; 50 Suppl 6:48; http://dx.doi.org/10.1016/S0959-8049(14)70265-5
-
(2014)
Eur J Cancer
, vol.50
, pp. 48
-
-
Croset, A.1
Macoin, J.2
Ollier, R.3
Pluess, M.4
Delon, C.5
Skegro, D.6
-
183
-
-
84961223528
-
Computationally Designed Bispecific Antibodies using Negative State Repertoires
-
26996964
-
Leaver-Fey A, Froning KJ, Atwell S, Aldaz H, Pustilnik A, Lu F, Huang F, Yuan R, Hassanali S, Chamberlain AK, et al. Computationally Designed Bispecific Antibodies using Negative State Repertoires. Structure 2016; 24:641-51; PMID:26996964; http://dx.doi.org/10.1016/j.str.2016.02.013
-
(2016)
Structure
, vol.24
, pp. 641-651
-
-
Leaver-Fey, A.1
Froning, K.J.2
Atwell, S.3
Aldaz, H.4
Pustilnik, A.5
Lu, F.6
Huang, F.7
Yuan, R.8
Hassanali, S.9
Chamberlain, A.K.10
-
184
-
-
84893859920
-
Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface
-
24463572
-
Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C, et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat Biotechnol 2014; 32:191-8; PMID:24463572; http://dx.doi.org/10.1038/nbt.2797
-
(2014)
Nat Biotechnol
, vol.32
, pp. 191-198
-
-
Lewis, S.M.1
Wu, X.2
Pustilnik, A.3
Sereno, A.4
Huang, F.5
Rick, H.L.6
Guntas, G.7
Leaver-Fay, A.8
Smith, E.M.9
Ho, C.10
-
185
-
-
84871565611
-
LUZ-Y, a novel platform for the mammalian cell production of full-length IgG-bispecific antibodies
-
23118228
-
Wranik BJ, Christensen EL, Schaefer G, Jackman JK, Vendel AC, Eaton D. LUZ-Y, a novel platform for the mammalian cell production of full-length IgG-bispecific antibodies. J Biol Chem 2012; 287:43331-9; PMID:23118228; http://dx.doi.org/10.1074/jbc.M112.397869
-
(2012)
J Biol Chem
, vol.287
, pp. 43331-43339
-
-
Wranik, B.J.1
Christensen, E.L.2
Schaefer, G.3
Jackman, J.K.4
Vendel, A.C.5
Eaton, D.6
-
186
-
-
84949681670
-
A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys
-
26659273
-
Smith EJ, Olson K, Haber LJ, Varghese B, Duramad P, Tustian AD, Oyejide A, Kirshner JR, Canova L, Menon J, et al. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci Rep 2015; 5:17943; PMID:26659273; http://dx.doi.org/10.1038/srep17943
-
(2015)
Sci Rep
, vol.5
, pp. 17943
-
-
Smith, E.J.1
Olson, K.2
Haber, L.J.3
Varghese, B.4
Duramad, P.5
Tustian, A.D.6
Oyejide, A.7
Kirshner, J.R.8
Canova, L.9
Menon, J.10
-
187
-
-
84963542602
-
Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity
-
26963837
-
Tustian AD, Endicott C, Adams B, Mattila J, Bak H. Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity. MAbs 2016; 8:828-38; PMID:26963837; http://dx.doi.org/10.1080/19420862.2016.1160192
-
(2016)
MAbs
, vol.8
, pp. 828-838
-
-
Tustian, A.D.1
Endicott, C.2
Adams, B.3
Mattila, J.4
Bak, H.5
-
188
-
-
84923247651
-
Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG
-
25672245
-
Fischer N, Elson G, Magistrelli G, Dheilly E, Fougue N, Laurendon A, Gueneau F, Ravn U, Depoisier JF, Moine V, et al. Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG. Nat Commun 2015; 6:6613; PMID:25672245; http://dx.doi.org/10.1038/ncomms7113
-
(2015)
Nat Commun
, vol.6
, pp. 6613
-
-
Fischer, N.1
Elson, G.2
Magistrelli, G.3
Dheilly, E.4
Fougue, N.5
Laurendon, A.6
Gueneau, F.7
Ravn, U.8
Depoisier, J.F.9
Moine, V.10
-
189
-
-
49449118423
-
Combinatorial surrobody libraries
-
18664586
-
Xu L, Yee H, Chan C, Kashyap AK, Horowitz L, Horowitz M, Bhatt RR, Lerner RA. Combinatorial surrobody libraries. Proc Natl Acad Sci USA 2008; 105:10756-61; PMID:18664586; http://dx.doi.org/10.1073/pnas.0805293105
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, pp. 10756-10761
-
-
Xu, L.1
Yee, H.2
Chan, C.3
Kashyap, A.K.4
Horowitz, L.5
Horowitz, M.6
Bhatt, R.R.7
Lerner, R.A.8
-
190
-
-
84863810846
-
ErbB3 inhibitory surrobodies inhibit tumor cell proliferation in vitro and in vivo
-
22553357
-
Foreman PK, Gore M, Kobel PA, Xu L, Yee H, Hannum C, Ho H, Wang SM, Tran HV, Horowitz M, et al. ErbB3 inhibitory surrobodies inhibit tumor cell proliferation in vitro and in vivo. Mol Cancer Ther 2012; 11:1411-20; PMID:22553357; http://dx.doi.org/10.1158/1535-7163.MCT-12-0068
-
(2012)
Mol Cancer Ther
, vol.11
, pp. 1411-1420
-
-
Foreman, P.K.1
Gore, M.2
Kobel, P.A.3
Xu, L.4
Yee, H.5
Hannum, C.6
Ho, H.7
Wang, S.M.8
Tran, H.V.9
Horowitz, M.10
-
191
-
-
84958166291
-
Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death
-
26516157
-
Milutinvic S, Kashyap AK, Yanagi T, Wimer C, Zhou S, O'Neill R, Kurtzman AL, Faynboym A, Xu L, Hannum CH, et al. Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death. Mol Cancer Ther 2016; 15:114-24; PMID:26516157; http://dx.doi.org/10.1158/1535-7163.MCT-15-0400
-
(2016)
Mol Cancer Ther
, vol.15
, pp. 114-124
-
-
Milutinvic, S.1
Kashyap, A.K.2
Yanagi, T.3
Wimer, C.4
Zhou, S.5
O'Neill, R.6
Kurtzman, A.L.7
Faynboym, A.8
Xu, L.9
Hannum, C.H.10
-
192
-
-
0033018776
-
Generation and characterization of a novel single-gene-encoded single-chain immunoglobulin molecule with antigen binding activity and effector functions
-
10369421
-
Lee HS, Shu L, De Pascalis R, Giuliano M, Zhu M, Padlan EA, Hand PH, Schlom J, Hong HJ, Kashmiri SV. Generation and characterization of a novel single-gene-encoded single-chain immunoglobulin molecule with antigen binding activity and effector functions. Mol Immunol 1999; 36:61-71; PMID:10369421
-
(1999)
Mol Immunol
, vol.36
, pp. 61-71
-
-
Lee, H.S.1
Shu, L.2
De Pascalis, R.3
Giuliano, M.4
Zhu, M.5
Padlan, E.A.6
Hand, P.H.7
Schlom, J.8
Hong, H.J.9
Kashmiri, S.V.10
-
193
-
-
38649086154
-
Single chain Fab (scFab) fragments
-
17346344
-
Hust M, Jostock T, Menzel C, Voedisch B, Mohr A, Brenneis M, Kirsch MI, Meier D, Dübel S. Single chain Fab (scFab) fragments. BMC Biotechnol 2007; 7:14; PMID:17346344; http://dx.doi.org/10.1186/1472-6750-7-14
-
(2007)
BMC Biotechnol
, vol.7
, pp. 14
-
-
Hust, M.1
Jostock, T.2
Menzel, C.3
Voedisch, B.4
Mohr, A.5
Brenneis, M.6
Kirsch, M.I.7
Meier, D.8
Dübel, S.9
-
194
-
-
77953665293
-
Oligomeric forms of single chain immunoglobulin (scIgG)
-
20081378
-
Schirrmann T, Menzel C, Hust M, Prilop J, Jostock T, Dübel S. Oligomeric forms of single chain immunoglobulin (scIgG). MAbs 2010; 2:73-76; PMID:20081378
-
(2010)
MAbs
, vol.2
, pp. 73-76
-
-
Schirrmann, T.1
Menzel, C.2
Hust, M.3
Prilop, J.4
Jostock, T.5
Dübel, S.6
-
195
-
-
84920755367
-
An improved single-chain Fab platform for efficient display and recombinant expression
-
25481745
-
Koerber JT, Hornsby MJ, Wells JA. An improved single-chain Fab platform for efficient display and recombinant expression. J Mol Biol 2015; 427:576-86; PMID:25481745; http://dx.doi.org/10.1016/j.jmb.2014.11.017
-
(2015)
J Mol Biol
, vol.427
, pp. 576-586
-
-
Koerber, J.T.1
Hornsby, M.J.2
Wells, J.A.3
-
196
-
-
84990902829
-
TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations
-
27578890
-
Castoldi R, Schanzer J, Panke C, Jucknischke U, Neubert NJ, Croasdale R, Scheuer W, Auer J, Klein C, Niederfellner G, et al. TetraMabs:simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations. Protein Eng Des Sel 2016; PMID:27578890; http://dx.doi.org/10.1093/protein/gzw037
-
(2016)
Protein Eng Des Sel
-
-
Castoldi, R.1
Schanzer, J.2
Panke, C.3
Jucknischke, U.4
Neubert, N.J.5
Croasdale, R.6
Scheuer, W.7
Auer, J.8
Klein, C.9
Niederfellner, G.10
-
197
-
-
84869783247
-
Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies
-
22925968
-
Klein C, Sustmann C, Thomas M, Stubenrauch K, Croasdale R, Schazer J, Brinkmann U, Kettenberger H, Regula JT, Schaefer W. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs 2012; 4:653-663; PMID:22925968; http://dx.doi.org/10.4161/mabs.21379
-
(2012)
MAbs
, vol.4
, pp. 653-663
-
-
Klein, C.1
Sustmann, C.2
Thomas, M.3
Stubenrauch, K.4
Croasdale, R.5
Schazer, J.6
Brinkmann, U.7
Kettenberger, H.8
Regula, J.T.9
Schaefer, W.10
-
198
-
-
84964402874
-
Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival
-
27044098
-
Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek K, Yu V, Dalvie N, Amelung RL, Datta M, Song JW, et al. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci USA 2016; 113:4476-81; PMID:27044098; http://dx.doi.org/10.1073/pnas.1525360113
-
(2016)
Proc Natl Acad Sci USA
, vol.113
, pp. 4476-4481
-
-
Kloepper, J.1
Riedemann, L.2
Amoozgar, Z.3
Seano, G.4
Susek, K.5
Yu, V.6
Dalvie, N.7
Amelung, R.L.8
Datta, M.9
Song, J.W.10
-
199
-
-
84975221851
-
Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity
-
27315479
-
Huang Y, Yu J, Lanzi A, Yao X, Andrews CD, Tsai L, Gajjar MR, Sun M, Seaman MS, Padte NN, et al. Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity. Cell 2016; 165:1621-31; PMID:27315479; http://dx.doi.org/10.1016/j.cell.2016.05.024
-
(2016)
Cell
, vol.165
, pp. 1621-1631
-
-
Huang, Y.1
Yu, J.2
Lanzi, A.3
Yao, X.4
Andrews, C.D.5
Tsai, L.6
Gajjar, M.R.7
Sun, M.8
Seaman, M.S.9
Padte, N.N.10
-
200
-
-
84979224082
-
The use of CrossMAb technology for the generation of bi- and multispecific antibodies
-
27285945
-
Klein C, Schaefer W, Regula JT. The use of CrossMAb technology for the generation of bi- and multispecific antibodies. MAbs 2016; 8:1010-20; PMID:27285945; http://dx.doi.org/10.1080/19420862.2016.1197457
-
(2016)
MAbs
, vol.8
, pp. 1010-1020
-
-
Klein, C.1
Schaefer, W.2
Regula, J.T.3
-
201
-
-
84977117312
-
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
-
26861458
-
Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Quaret D, Bodmer W, Lehmann S, Hofer T, Hosse RJ, et al. A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors. Clin Cancer Res 2016; 22:3286-97; PMID:26861458; http://dx.doi.org/10.1158/1078-0432.CCR-15-1696
-
(2016)
Clin Cancer Res
, vol.22
, pp. 3286-3297
-
-
Bacac, M.1
Fauti, T.2
Sam, J.3
Colombetti, S.4
Weinzierl, T.5
Quaret, D.6
Bodmer, W.7
Lehmann, S.8
Hofer, T.9
Hosse, R.J.10
-
202
-
-
84920657077
-
Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk
-
25371409
-
Hu S, Fu W, Xu W, Yang Y, Cruz M, Berezov SD, Jorissen D, Takeda H, Zhu W. Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk. Cancer Res 2014; 75:159-70; PMID:25371409; http://dx.doi.org/10.1158/0008-5472.CAN-14-1670
-
(2014)
Cancer Res
, vol.75
, pp. 159-170
-
-
Hu, S.1
Fu, W.2
Xu, W.3
Yang, Y.4
Cruz, M.5
Berezov, S.D.6
Jorissen, D.7
Takeda, H.8
Zhu, W.9
-
203
-
-
84924601311
-
Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies
-
25611120
-
Wu X, Sereno AJ, Huang F, Zhang K, Batt M, Fitchett JR, He D, Rick HL, Conner EM, Demarest SJ. Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies. MAbs 2015; 7:364-76; PMID:25611120; http://dx.doi.org/10.1080/19420862.2015.1007826
-
(2015)
MAbs
, vol.7
, pp. 364-376
-
-
Wu, X.1
Sereno, A.J.2
Huang, F.3
Zhang, K.4
Batt, M.5
Fitchett, J.R.6
He, D.7
Rick, H.L.8
Conner, E.M.9
Demarest, S.J.10
-
204
-
-
84962622376
-
Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies
-
26921308
-
Golay J, Choblet S, Iwaszkiewicz J, Cerutti P, Ozil A, Loisel S, Pugnière M, Ubiali G, Zoete V, Michielin O, et al. Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies. J Immunol 2016; 196:3199-211; PMID:26921308; http://dx.doi.org/10.4049/jimmunol.1501592
-
(2016)
J Immunol
, vol.196
, pp. 3199-3211
-
-
Golay, J.1
Choblet, S.2
Iwaszkiewicz, J.3
Cerutti, P.4
Ozil, A.5
Loisel, S.6
Pugnière, M.7
Ubiali, G.8
Zoete, V.9
Michielin, O.10
-
205
-
-
84924964249
-
Improving target cell specificity using a novel monovalent bispecific IgG design
-
25621507
-
Mazor Y, Oganesyan V, Yang C, Hansen A, Wang J, Liu H, Sachsenmeier K, Carlson M, Gadre DV, Borrok MJ, et al. Improving target cell specificity using a novel monovalent bispecific IgG design. MAbs 2015; 7:377-89; PMID:25621507; http://dx.doi.org/10.1080/19420862.2015.1007816
-
(2015)
MAbs
, vol.7
, pp. 377-389
-
-
Mazor, Y.1
Oganesyan, V.2
Yang, C.3
Hansen, A.4
Wang, J.5
Liu, H.6
Sachsenmeier, K.7
Carlson, M.8
Gadre, D.V.9
Borrok, M.J.10
-
206
-
-
84945195275
-
Insights into the molecular basis of a bispecific antibody's target selectivity
-
25730144
-
Mazor Y, Hansen A, Yang C, Chowdhury PS, Wang J, Stephens G, Wu H, Dall'Acqua WF. Insights into the molecular basis of a bispecific antibody's target selectivity. MAbs 2015; 7:461-669; PMID:25730144; http://dx.doi.org/10.1080/19420862.2015.1022695
-
(2015)
MAbs
, vol.7
, pp. 461-669
-
-
Mazor, Y.1
Hansen, A.2
Yang, C.3
Chowdhury, P.S.4
Wang, J.5
Stephens, G.6
Wu, H.7
Dall'Acqua, W.F.8
-
207
-
-
84988940645
-
Development of PF-06671008, a highly potent anti-P-cadherin/anti-CD3 bispecific DART molecule with extended half-life for the treatment of cancer
-
Root AR, Cao W, Li B, LaPan P, Meade C, Sanford J, et al. Development of PF-06671008, a highly potent anti-P-cadherin/anti-CD3 bispecific DART molecule with extended half-life for the treatment of cancer. Antibodies 2016; 5:6, doi:10.3390/antib5010006
-
(2016)
Antibodies
, vol.5
, pp. 6
-
-
Root, A.R.1
Cao, W.2
Li, B.3
LaPan, P.4
Meade, C.5
Sanford, J.6
-
208
-
-
70349785100
-
The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators
-
19699208
-
Dimasi N, Gao C, Fleming R, Woods RM, Yao XT, Shirinian L, Kiener PA, Wu H. The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. J Mol Biol 2009; 393:672-92; PMID:19699208; http://dx.doi.org/10.1016/j.jmb.2009.08.032
-
(2009)
J Mol Biol
, vol.393
, pp. 672-692
-
-
Dimasi, N.1
Gao, C.2
Fleming, R.3
Woods, R.M.4
Yao, X.T.5
Shirinian, L.6
Kiener, P.A.7
Wu, H.8
-
209
-
-
79955548494
-
Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains
-
21300827
-
Schanzer J, Jekle A, Nezu J, Lochner A, Croasdale R, Dioszegi M, Zhang J, Hoffmann E, Dormeyer W, Stracke J, et al. Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains. Antimicrob Agents Chemother 2011; 55:2369-78; PMID:21300827; http://dx.doi.org/10.1128/AAC.00215-10
-
(2011)
Antimicrob Agents Chemother
, vol.55
, pp. 2369-2378
-
-
Schanzer, J.1
Jekle, A.2
Nezu, J.3
Lochner, A.4
Croasdale, R.5
Dioszegi, M.6
Zhang, J.7
Hoffmann, E.8
Dormeyer, W.9
Stracke, J.10
-
210
-
-
84865688929
-
Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition
-
22464987
-
Croasdale R, Wartha K, Schanzer JM, Kuenkele KP, Ries C, Mayer K. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition. Arch Biochem Biophys 2012; 526:206-18; PMID:22464987; http://dx.doi.org/10.1016/j.abb.2012.03.016
-
(2012)
Arch Biochem Biophys
, vol.526
, pp. 206-218
-
-
Croasdale, R.1
Wartha, K.2
Schanzer, J.M.3
Kuenkele, K.P.4
Ries, C.5
Mayer, K.6
-
211
-
-
84874276034
-
A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance
-
23175797
-
Yazaki PJ, Lee B, Channappa D, Cheung CW, Crow D, Chea J, Poku E, Li L, Andersen JT, Sandlie I, et al. A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting:comparison of tumor uptake and blood clearance. Protein Eng Des Sel 2013; 26:187-93; PMID:23175797; http://dx.doi.org/10.1093/protein/gzs096
-
(2013)
Protein Eng Des Sel
, vol.26
, pp. 187-193
-
-
Yazaki, P.J.1
Lee, B.2
Channappa, D.3
Cheung, C.W.4
Crow, D.5
Chea, J.6
Poku, E.7
Li, L.8
Andersen, J.T.9
Sandlie, I.10
-
212
-
-
77954630517
-
A modular IgG-scFv bispecific antibody topology
-
20019028
-
Orcutt KD, Ackerman ME, Cieslewicz M, Quiroz E, Slusarczyk AL, Frangioni JV, Wittrup KD. A modular IgG-scFv bispecific antibody topology. Protein Eng Des Sel 2010; 23:221-8; PMID:20019028; http://dx.doi.org/10.1093/protein/gzp077
-
(2010)
Protein Eng Des Sel
, vol.23
, pp. 221-228
-
-
Orcutt, K.D.1
Ackerman, M.E.2
Cieslewicz, M.3
Quiroz, E.4
Slusarczyk, A.L.5
Frangioni, J.V.6
Wittrup, K.D.7
-
213
-
-
0034087954
-
An efficient route to the production of an IgG-like bispecific antibody
-
10835110
-
Zuo Z, Jimenez X, Witte L, Zhu Z. An efficient route to the production of an IgG-like bispecific antibody. Protein Eng 2000; 13:361-7; PMID:10835110
-
(2000)
Protein Eng
, vol.13
, pp. 361-367
-
-
Zuo, Z.1
Jimenez, X.2
Witte, L.3
Zhu, Z.4
-
214
-
-
9144256621
-
Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody
-
14576153
-
Lu D, Zhang H, Ludwig D, Persaud A, Jimenez X, Burtrum D, Balderes P, Liu M, Bohlen P, Witte L, et al. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J Biol Chem 2004; 279:2856-65; PMID:14576153; http://dx.doi.org/10.1074/jbc.M310132200.
-
(2004)
J Biol Chem
, vol.279
, pp. 2856-2865
-
-
Lu, D.1
Zhang, H.2
Ludwig, D.3
Persaud, A.4
Jimenez, X.5
Burtrum, D.6
Balderes, P.7
Liu, M.8
Bohlen, P.9
Witte, L.10
-
215
-
-
34948911585
-
Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells
-
17644522
-
Asano R, Watanabe Y, Kawaguchi H, Fukazawa H, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T, et al. Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells. J Biol Chem 2007; 282:27659-65; PMID:17644522
-
(2007)
J Biol Chem
, vol.282
, pp. 27659-27665
-
-
Asano, R.1
Watanabe, Y.2
Kawaguchi, H.3
Fukazawa, H.4
Nakanishi, T.5
Umetsu, M.6
Hayashi, H.7
Katayose, Y.8
Unno, M.9
Kudo, T.10
-
216
-
-
79960789752
-
In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody
-
21743971
-
Watanabe Y, Asano R, Arai K, Shimomura I, Ogata H, Kawaguchi H, Hayashi H, Ohtsuka H, Yoshida H, Katayose Y, et al. In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody. Oncol Rep 2011; 26:949-55; PMID:21743971; http://dx.doi.org/10.3892/or.2011.1382
-
(2011)
Oncol Rep
, vol.26
, pp. 949-955
-
-
Watanabe, Y.1
Asano, R.2
Arai, K.3
Shimomura, I.4
Ogata, H.5
Kawaguchi, H.6
Hayashi, H.7
Ohtsuka, H.8
Yoshida, H.9
Katayose, Y.10
-
217
-
-
70449770418
-
Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbR
-
20061822
-
Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, Huang F, Phan S, Gao S, Doern A, et al. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbR. MAbs 2009; 1:128-41; PMID:20061822
-
(2009)
MAbs
, vol.1
, pp. 128-141
-
-
Michaelson, J.S.1
Demarest, S.J.2
Miller, B.3
Amatucci, A.4
Snyder, W.B.5
Wu, X.6
Huang, F.7
Phan, S.8
Gao, S.9
Doern, A.10
-
218
-
-
79957683054
-
Bispecific digoxigenin-binding antibodies for targeted payload delivery
-
21536919
-
Metz S, Haas AK, Daub K, Croasdale R, Stracke J, Lau W, Georges G, Josel HP, Dziadek S, Hopfner KP, et al. Bispecific digoxigenin-binding antibodies for targeted payload delivery. Proc Natl Acad Sci USA 2011; 108:8194-9; PMID:21536919; http://dx.doi.org/10.1073/pnas.1018565108
-
(2011)
Proc Natl Acad Sci USA
, vol.108
, pp. 8194-8199
-
-
Metz, S.1
Haas, A.K.2
Daub, K.3
Croasdale, R.4
Stracke, J.5
Lau, W.6
Georges, G.7
Josel, H.P.8
Dziadek, S.9
Hopfner, K.P.10
-
219
-
-
84896524335
-
Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells
-
24492289
-
Kang JC, Poovassery JS, Bansal P, You S, Manjarres IM, Ober RJ, Ward ES. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells. MAbs 2014; 6:340-53; PMID:24492289; http://dx.doi.org/10.4161/mabs.27658
-
(2014)
MAbs
, vol.6
, pp. 340-353
-
-
Kang, J.C.1
Poovassery, J.S.2
Bansal, P.3
You, S.4
Manjarres, I.M.5
Ober, R.J.6
Ward, E.S.7
-
220
-
-
84864148512
-
Bispecific antibody derivatives based on full-length IgG formats
-
22723106
-
Grote M, Haas AK, Klein C, Schaefer W, Brinkmann U. Bispecific antibody derivatives based on full-length IgG formats. Methods Mol Biol 2012; 901:247-63; PMID:22723106; http://dx.doi.org/10.1007/978-1-61779-931-0_16
-
(2012)
Methods Mol Biol
, vol.901
, pp. 247-263
-
-
Grote, M.1
Haas, A.K.2
Klein, C.3
Schaefer, W.4
Brinkmann, U.5
-
221
-
-
76949084270
-
Engineering of stable bispecific antibodies targeting IL-17A and IL-23
-
20022918
-
Mabry R, Lewis KE, Moore M, McKernan PA, Bukowski TR, Bontadelli K, Brender T, Okada S, Lum K, West J, et al. Engineering of stable bispecific antibodies targeting IL-17A and IL-23. Protein Eng Des Sel 2009; 23:115-27; PMID:20022918; http://dx.doi.org/10.1093/protein/gzp073
-
(2009)
Protein Eng Des Sel
, vol.23
, pp. 115-127
-
-
Mabry, R.1
Lewis, K.E.2
Moore, M.3
McKernan, P.A.4
Bukowski, T.R.5
Bontadelli, K.6
Brender, T.7
Okada, S.8
Lum, K.9
West, J.10
-
222
-
-
79953016709
-
Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity
-
21123183
-
Dong J, Sereno A, Snyder WB, Miller BR, Tamraz S, Doern A, Favis M, Wu X, Tran H, Langley E, et al. Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. J Biol Chem 2011; 286:47034717; PMID:21123183; http://dx.doi.org/10.1074/jbc.M110.184317
-
(2011)
J Biol Chem
, vol.286
, pp. 47034717
-
-
Dong, J.1
Sereno, A.2
Snyder, W.B.3
Miller, B.R.4
Tamraz, S.5
Doern, A.6
Favis, M.7
Wu, X.8
Tran, H.9
Langley, E.10
-
223
-
-
84918825382
-
IgG subclasses and allotpyes: from structure to effector functions
-
25368619
-
Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotpyes:from structure to effector functions. Front Immunol 2014; 5:520; PMID:25368619; http://dx.doi.org/10.3389/fimmu.2014.00520
-
(2014)
Front Immunol
, vol.5
, pp. 520
-
-
Vidarsson, G.1
Dekkers, G.2
Rispens, T.3
-
224
-
-
77955976111
-
Stability engineering of scFvs for the development of bispecific and multivalent antibodies
-
20457695
-
Miller BR, Demarest SJ, Lugovskoy A, Huang F, Wu X, Snyder WB, Croner LJ, Wang N, Amatucci A, Michaelson JS, et al. Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel 2010; 23:549-57; PMID:20457695; http://dx.doi.org/10.1093/protein/gzq028
-
(2010)
Protein Eng Des Sel
, vol.23
, pp. 549-557
-
-
Miller, B.R.1
Demarest, S.J.2
Lugovskoy, A.3
Huang, F.4
Wu, X.5
Snyder, W.B.6
Croner, L.J.7
Wang, N.8
Amatucci, A.9
Michaelson, J.S.10
-
225
-
-
79955675632
-
A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity
-
21393993
-
Dong J, Sereno A, Aivazian D, Langley E, Miller BR, Snyder WB, Chan E, Cantele M, Morena R, Joseph IB, et al. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. MAbs 2011b; 3:273-88; PMID:21393993
-
(2011)
MAbs
, vol.3
, pp. 273-288
-
-
Dong, J.1
Sereno, A.2
Aivazian, D.3
Langley, E.4
Miller, B.R.5
Snyder, W.B.6
Chan, E.7
Cantele, M.8
Morena, R.9
Joseph, I.B.10
-
227
-
-
0034657794
-
The IgG Fc contains distinct Fc receptor (FcR) binding sites: the leukocyte receptors Fc gamma RI and Fc gamma RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A
-
10799893
-
Wines BD, Powell MS, Parren PW, Barnes N, Hogarth PM. The IgG Fc contains distinct Fc receptor (FcR) binding sites:the leukocyte receptors Fc gamma RI and Fc gamma RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A. J Immunol 2000; 164:5313-8; PMID:10799893
-
(2000)
J Immunol
, vol.164
, pp. 5313-5318
-
-
Wines, B.D.1
Powell, M.S.2
Parren, P.W.3
Barnes, N.4
Hogarth, P.M.5
-
228
-
-
45749102844
-
Structural characterization of a human Fc fragment engineered for lack of effector functions
-
18560159
-
Oganesyan V, Gao C, Shirinian L, Wu H, Dall'Acqua WF. Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr D Biol Crystallogr 2008; 64:700-4; PMID:18560159; http://dx.doi.org/10.1107/S0907444908007877
-
(2008)
Acta Crystallogr D Biol Crystallogr
, vol.64
, pp. 700-704
-
-
Oganesyan, V.1
Gao, C.2
Shirinian, L.3
Wu, H.4
Dall'Acqua, W.F.5
-
229
-
-
84891631658
-
An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations
-
23872058
-
Vafa O, Gilliland GL, Brezski RJ, Strake B, Wilkinson T, Lacy ER, Scallon B, Teplyakov A, Malia TJ, Strohl WR. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Methods 2013; 65:114-26; PMID:23872058; http://dx.doi.org/10.1016/j.ymeth.2013.06.035
-
(2013)
Methods
, vol.65
, pp. 114-126
-
-
Vafa, O.1
Gilliland, G.L.2
Brezski, R.J.3
Strake, B.4
Wilkinson, T.5
Lacy, E.R.6
Scallon, B.7
Teplyakov, A.8
Malia, T.J.9
Strohl, W.R.10
-
230
-
-
33747616656
-
Engineering of therapeutic antibodies to minimize immunogenicity and optimize function
-
16904789
-
Presta LG. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 2006; 58:640-56; PMID:16904789; http://dx.doi.org/10.1016/j.addr.2006.01.026
-
(2006)
Adv Drug Deliv Rev
, vol.58
, pp. 640-656
-
-
Presta, L.G.1
-
231
-
-
77953652926
-
IgG2m4, an engineered antibody isotype with reduced Fc function
-
20073128
-
An Z, Forrest G, Moore R, Cukan M, Haytko P, Vitelli S, Zhao JZ, Lu P, Hua J, Gibson CR, et al. IgG2m4, an engineered antibody isotype with reduced Fc function. MAbs 2009; 1:572-9; PMID:20073128
-
(2009)
MAbs
, vol.1
, pp. 572-579
-
-
An, Z.1
Forrest, G.2
Moore, R.3
Cukan, M.4
Haytko, P.5
Vitelli, S.6
Zhao, J.Z.7
Lu, P.8
Hua, J.9
Gibson, C.R.10
-
232
-
-
84929236443
-
Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer
-
25471734
-
Poovassery JS, Kang JC, Kim D, Ober RJ, Ward ES. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer. Int J Cancer 2015; 137:267-77; PMID:25471734; http://dx.doi.org/10.1002/ijc.29378
-
(2015)
Int J Cancer
, vol.137
, pp. 267-277
-
-
Poovassery, J.S.1
Kang, J.C.2
Kim, D.3
Ober, R.J.4
Ward, E.S.5
-
233
-
-
76249087751
-
Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor
-
19921848
-
Boado RJ, Zhou QH, Lu JZ, Hui EK, Pardidge WM. Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor. Mol Pharm 2010; 7:237-44; PMID:19921848; http://dx.doi.org/10.1021/mp900235k
-
(2010)
Mol Pharm
, vol.7
, pp. 237-244
-
-
Boado, R.J.1
Zhou, Q.H.2
Lu, J.Z.3
Hui, E.K.4
Pardidge, W.M.5
-
234
-
-
84964389239
-
Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma
-
27040766
-
Lu CY, Chen GJ, Tai PH, Yang YC, Hsu YS, Chang M, Hsu CL. Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma. Biochem Biophys Res Commun 2016; 473:808-813; PMID:27040766; http://dx.doi.org/10.1016/j.bbrc.2016.03.124
-
(2016)
Biochem Biophys Res Commun
, vol.473
, pp. 808-813
-
-
Lu, C.Y.1
Chen, G.J.2
Tai, P.H.3
Yang, Y.C.4
Hsu, Y.S.5
Chang, M.6
Hsu, C.L.7
-
235
-
-
84904174507
-
Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex
-
24944121
-
Cheal SM, Xu H, Guo HF, Zanzonico PB, Larson SM, Cheung NK. Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex. Mol Cancer Ther 2014; 13:1803-12; PMID:24944121; http://dx.doi.org/10.1158/1535-7163.MCT-13-0933
-
(2014)
Mol Cancer Ther
, vol.13
, pp. 1803-1812
-
-
Cheal, S.M.1
Xu, H.2
Guo, H.F.3
Zanzonico, P.B.4
Larson, S.M.5
Cheung, N.K.6
-
236
-
-
33744964246
-
Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies
-
16481314
-
Shen J, Vil MD, Jimenez X, Iacolina M, Zhang H, Zhu Z. Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies. J Biol Chem 2006; 281:10706-14; PMID:16481314; http://dx.doi.org/10.1074/jbc.M513415200
-
(2006)
J Biol Chem
, vol.281
, pp. 10706-10714
-
-
Shen, J.1
Vil, M.D.2
Jimenez, X.3
Iacolina, M.4
Zhang, H.5
Zhu, Z.6
-
237
-
-
33845884563
-
Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies
-
17126853
-
Shen J, Vil MD, Jimenez X, Zhang H, Iacolina M, Mangalampalli V, Balderes P, Ludwig DL, Zhu Z. Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies. J Immunol Methods 2007; 318:65-74; PMID:17126853; http://dx.doi.org/10.1016/j.jim.2006.09.020
-
(2007)
J Immunol Methods
, vol.318
, pp. 65-74
-
-
Shen, J.1
Vil, M.D.2
Jimenez, X.3
Zhang, H.4
Iacolina, M.5
Mangalampalli, V.6
Balderes, P.7
Ludwig, D.L.8
Zhu, Z.9
-
238
-
-
84905667525
-
A bispecific HER2-targeting FynomAb with superior antitumor activity and novel mode of action
-
24994770
-
Brack S, Attinger-Toller I, Schade B, Mourlane F, Klupsch K, Woods R, Hachemi H, von der Bey U, Koenig-Friedrich S, Bertschinger J, et al. A bispecific HER2-targeting FynomAb with superior antitumor activity and novel mode of action. Mol Cancer Ther 2014; 13:2030-9; PMID:24994770; http://dx.doi.org/10.1158/1535-7163.MCT-14-0046-T
-
(2014)
Mol Cancer Ther
, vol.13
, pp. 2030-2039
-
-
Brack, S.1
Attinger-Toller, I.2
Schade, B.3
Mourlane, F.4
Klupsch, K.5
Woods, R.6
Hachemi, H.7
von der Bey, U.8
Koenig-Friedrich, S.9
Bertschinger, J.10
-
239
-
-
84964413447
-
Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases
-
26390837
-
Silacci M, Lembke W, Woods R, Attinger-Toller I, Baenziger-Tobler N, Batey S, Santimaria R, von der Bey U, Koenig-Friedrich S, Zha W, et al. Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases. MAbs 2016; 8:141-149; PMID:26390837; http://dx.doi.org/10.1080/19420862.2015.1093266
-
(2016)
MAbs
, vol.8
, pp. 141-149
-
-
Silacci, M.1
Lembke, W.2
Woods, R.3
Attinger-Toller, I.4
Baenziger-Tobler, N.5
Batey, S.6
Santimaria, R.7
von der Bey, U.8
Koenig-Friedrich, S.9
Zha, W.10
-
240
-
-
84866552180
-
Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis
-
22864384
-
Kanakaraj P, Puffer BA, Yao XT, Kankanala S, Boyd E, Shah RR, Wang G, Patel D, Krishnamurthy R, Kaithamana S, et al. Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. MAbs 2012; 4:600-613; PMID:22864384; http://dx.doi.org/10.4161/mabs.21227
-
(2012)
MAbs
, vol.4
, pp. 600-613
-
-
Kanakaraj, P.1
Puffer, B.A.2
Yao, X.T.3
Kankanala, S.4
Boyd, E.5
Shah, R.R.6
Wang, G.7
Patel, D.8
Krishnamurthy, R.9
Kaithamana, S.10
-
241
-
-
84876336136
-
Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides
-
23575268
-
LaFleur DW, Abramyan D, Kanakaraj P, Smith RG, Shah RR, Wang G, Yao XT, Kankanala S, Boyd E, Zaritskaya L, et al. Monoclonal antibody therapeutics with up to five specificities:functional enhancement through fusion of target-specific peptides. MAbs 2013; 5:208-218; PMID:23575268; http://dx.doi.org/10.4161/mabs.23043
-
(2013)
MAbs
, vol.5
, pp. 208-218
-
-
LaFleur, D.W.1
Abramyan, D.2
Kanakaraj, P.3
Smith, R.G.4
Shah, R.R.5
Wang, G.6
Yao, X.T.7
Kankanala, S.8
Boyd, E.9
Zaritskaya, L.10
-
242
-
-
84954313711
-
A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation
-
26073904
-
Shen Y, Zeng L, Novosyadlyy R, Forest A, Zhu A, Korytko A, Zhang H, Eastman SW, Topper M, Hindi S, et al. A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation. MAbs 2015; 7:931-45; PMID:26073904; http://dx.doi.org/10.1080/19420862.2015.1055442
-
(2015)
MAbs
, vol.7
, pp. 931-945
-
-
Shen, Y.1
Zeng, L.2
Novosyadlyy, R.3
Forest, A.4
Zhu, A.5
Korytko, A.6
Zhang, H.7
Eastman, S.W.8
Topper, M.9
Hindi, S.10
-
243
-
-
0242500331
-
Design, construction, and in vitro analysis of multivalent antibodies
-
12728922
-
Miller K, Meng G, Liu J, Hurst A, Hsei V, Wong WL, Ekert R, Lawrence D, Sherwood S, DeForge L, et al. Design, construction, and in vitro analysis of multivalent antibodies. J Immunol 2003; 170:4854-61; PMID:12728922
-
(2003)
J Immunol
, vol.170
, pp. 4854-4861
-
-
Miller, K.1
Meng, G.2
Liu, J.3
Hurst, A.4
Hsei, V.5
Wong, W.L.6
Ekert, R.7
Lawrence, D.8
Sherwood, S.9
DeForge, L.10
-
244
-
-
84969540602
-
RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis
-
27037412
-
Brünker P, Wartha K, Friess T, Grau-Richards S, Waldhauer I, Koller CF, Weiser B, Majety M, Runza V, Niu H, et al. RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis. Mol Cancer Ther 2016; 15:946-57; PMID:27037412; http://dx.doi.org/10.1158/1535-7163.MCT-15-0647
-
(2016)
Mol Cancer Ther
, vol.15
, pp. 946-957
-
-
Brünker, P.1
Wartha, K.2
Friess, T.3
Grau-Richards, S.4
Waldhauer, I.5
Koller, C.F.6
Weiser, B.7
Majety, M.8
Runza, V.9
Niu, H.10
-
245
-
-
67650346177
-
Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma
-
19372261
-
Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH. Hexavalent bispecific antibodies represent a new class of anticancer therapeutics:1. Properties of anti-CD20/CD22 antibodies in lymphoma. Blood 2009; 113:6161-71; PMID:19372261; http://dx.doi.org/10.1182/blood-2008-10-187138
-
(2009)
Blood
, vol.113
, pp. 6161-6171
-
-
Rossi, E.A.1
Goldenberg, D.M.2
Cardillo, T.M.3
Stein, R.4
Chang, C.H.5
-
246
-
-
84860332847
-
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas
-
22271448
-
Gupta P, Goldenberg DM, Rossi EA, Cardillo TM, Byrd JC, Muthusamy N, Furman RR, Chang CH. Dual-targeting immunotherapy of lymphoma:potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. Blood 2012; 119:3767-2778; PMID:22271448; http://dx.doi.org/10.1182/blood-2011-09-381988
-
(2012)
Blood
, vol.119
, pp. 3767-3778
-
-
Gupta, P.1
Goldenberg, D.M.2
Rossi, E.A.3
Cardillo, T.M.4
Byrd, J.C.5
Muthusamy, N.6
Furman, R.R.7
Chang, C.H.8
-
247
-
-
84863337696
-
The dock-and-lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures
-
22168393
-
Rossi EA, Goldenberg DM, Chang CH. The dock-and-lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures. Bioconjug Chem 2012; 23:309-23; PMID:22168393; http://dx.doi.org/10.1021/bc2004999
-
(2012)
Bioconjug Chem
, vol.23
, pp. 309-323
-
-
Rossi, E.A.1
Goldenberg, D.M.2
Chang, C.H.3
-
248
-
-
78049395507
-
Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias
-
20628151
-
Gupta P, Goldenberg DM, Rossi EA, Chang CH. Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias. Blood 2010; 116:3258-67; PMID:20628151; http://dx.doi.org/10.1182/blood-2010-03-276857
-
(2010)
Blood
, vol.116
, pp. 3258-3267
-
-
Gupta, P.1
Goldenberg, D.M.2
Rossi, E.A.3
Chang, C.H.4
-
249
-
-
35948977323
-
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin
-
17934452
-
Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu RR, Santora L, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25:1290-7; PMID:17934452; http://dx.doi.org/10.1038/nbt1345
-
(2007)
Nat Biotechnol
, vol.25
, pp. 1290-1297
-
-
Wu, C.1
Ying, H.2
Grinnell, C.3
Bryant, S.4
Miller, R.5
Clabbers, A.6
Bose, S.7
McCarthy, D.8
Zhu, R.R.9
Santora, L.10
-
250
-
-
77951520735
-
Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules
-
20068402
-
Wu C, Ying H, Bose S, Miller R, Medina L, Santora L, Ghayur T. Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules. MAbs 2009; 1:339-47; PMID:20068402
-
(2009)
MAbs
, vol.1
, pp. 339-347
-
-
Wu, C.1
Ying, H.2
Bose, S.3
Miller, R.4
Medina, L.5
Santora, L.6
Ghayur, T.7
-
251
-
-
84945185379
-
Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1α and IL-1β
-
25764208
-
Lacy SE, Wu C, Ambrosi DJ, Hsieh CM, Bose S, Miller R, Conlon DM, Tarcsa E, Chari R, Ghayur T, et al. Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1α and IL-1β. MAbs 2015; 7:605-19; PMID:25764208; http://dx.doi.org/10.1080/19420862.2015.1026501
-
(2015)
MAbs
, vol.7
, pp. 605-619
-
-
Lacy, S.E.1
Wu, C.2
Ambrosi, D.J.3
Hsieh, C.M.4
Bose, S.5
Miller, R.6
Conlon, D.M.7
Tarcsa, E.8
Chari, R.9
Ghayur, T.10
-
252
-
-
84867136866
-
Anti-HIV double variable domain immunoglobulins binding both gp41 and gp120 for targeted delivery of immunoconjugates
-
23056448
-
Craig RB, Summa CM, Corti M, Pincus SH. Anti-HIV double variable domain immunoglobulins binding both gp41 and gp120 for targeted delivery of immunoconjugates. PLoS One 2012; 7:e46778; PMID:23056448; http://dx.doi.org/10.1371/journal.pone.0046778
-
(2012)
PLoS One
, vol.7
, pp. e46778
-
-
Craig, R.B.1
Summa, C.M.2
Corti, M.3
Pincus, S.H.4
-
253
-
-
84954316938
-
A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells
-
26083076
-
Piccione EC, Juarez S, Liu J, Tseng S, Ryan CE, Narayanan C, Wang L, Weiskopf K, Majeti R. A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells. MAbs 2015; 7:946-56; PMID:26083076; http://dx.doi.org/10.1080/19420862.2015.1062192
-
(2015)
MAbs
, vol.7
, pp. 946-956
-
-
Piccione, E.C.1
Juarez, S.2
Liu, J.3
Tseng, S.4
Ryan, C.E.5
Narayanan, C.6
Wang, L.7
Weiskopf, K.8
Majeti, R.9
-
254
-
-
84930629876
-
Identification of anti-EGFR and anti-ErbB3 dual variable domains immunoglobulin (DVD-Ig) proteins with unique activities
-
25997020
-
Gu J, Yang J, Chang Q, Liu Z, Ghayur T, Gu J. Identification of anti-EGFR and anti-ErbB3 dual variable domains immunoglobulin (DVD-Ig) proteins with unique activities. PLoS One 2015; 20:e0124135; PMID:25997020; http://dx.doi.org/10.1371/journal.pone.0124135
-
(2015)
PLoS One
, vol.20
, pp. e0124135
-
-
Gu, J.1
Yang, J.2
Chang, Q.3
Liu, Z.4
Ghayur, T.5
Gu, J.6
-
255
-
-
84951568377
-
A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR
-
25773122
-
Zeng J, Liu R, Wang J, Fang Y. A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR. J Cancer Res Clin Oncol 2015; 141:1899-907; PMID:25773122; http://dx.doi.org/10.1007/s00432-015-1949-7
-
(2015)
J Cancer Res Clin Oncol
, vol.141
, pp. 1899-1907
-
-
Zeng, J.1
Liu, R.2
Wang, J.3
Fang, Y.4
-
256
-
-
84901259058
-
Identification of anti-ErbB2 dual variable domain immunoglobulin (DVD-Ig™) proteins with unique activities
-
24824849
-
Gu J, Yang J, Chang Q, Lu X, Wang J, Chen M, Ghayur T, Gu J. Identification of anti-ErbB2 dual variable domain immunoglobulin (DVD-Ig™) proteins with unique activities. PLoS One 2014; 9:e97292; PMID:24824849; http://dx.doi.org/10.1371/journal.pone.0097292
-
(2014)
PLoS One
, vol.9
, pp. e97292
-
-
Gu, J.1
Yang, J.2
Chang, Q.3
Lu, X.4
Wang, J.5
Chen, M.6
Ghayur, T.7
Gu, J.8
-
257
-
-
80052580966
-
Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design
-
21814039
-
DiGiammarino EL, Harlan JE, Walter KA, Ladror US, Edalji RP, Hutchings CW, Lake MR, Greischar AJ, Liu J, Ghayur T, et al. Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design. MAbs 2011; 3:487-494; PMID:21814039; http://dx.doi.org/10.4161/mabs.3.5.16326
-
(2011)
MAbs
, vol.3
, pp. 487-494
-
-
DiGiammarino, E.L.1
Harlan, J.E.2
Walter, K.A.3
Ladror, U.S.4
Edalji, R.P.5
Hutchings, C.W.6
Lake, M.R.7
Greischar, A.J.8
Liu, J.9
Ghayur, T.10
-
258
-
-
84877877265
-
The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigen
-
23572180
-
Correia I, Sung J, Burton R, Jakob CG, Carragher B, Ghayur T, Radziejewski C. The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigen. MAbs 2013; 5:364-72; PMID:23572180; http://dx.doi.org/10.4161/mabs.24258
-
(2013)
MAbs
, vol.5
, pp. 364-372
-
-
Correia, I.1
Sung, J.2
Burton, R.3
Jakob, C.G.4
Carragher, B.5
Ghayur, T.6
Radziejewski, C.7
-
259
-
-
84877887262
-
Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule
-
23549062
-
Jacob CG, Edalji R, Judge RA, diGiammarino E, Li Y, Gu J, Ghayur T. Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule. MAbs 2013; 5:358-63; PMID:23549062; http://dx.doi.org/10.4161/mabs.23977
-
(2013)
MAbs
, vol.5
, pp. 358-363
-
-
Jacob, C.G.1
Edalji, R.2
Judge, R.A.3
diGiammarino, E.4
Li, Y.5
Gu, J.6
Ghayur, T.7
-
260
-
-
84977983830
-
Rational design of antirheumatoic prodrugs specific for sites of inflammation
-
26097196
-
Onuoha SC, Ferrari M, Sblattero D, Pfizalis C. Rational design of antirheumatoic prodrugs specific for sites of inflammation. Arthritis Rheumatol 2015; 67:2661-72; PMID:26097196; http://dx.doi.org/10.1002/art.39232
-
(2015)
Arthritis Rheumatol
, vol.67
, pp. 2661-2672
-
-
Onuoha, S.C.1
Ferrari, M.2
Sblattero, D.3
Pfizalis, C.4
-
261
-
-
84963542010
-
CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications
-
26984268
-
Steinmetz A, Vallée F, Beil C, Lange C, Baurin N, Beninga J, Capdevila C, Corvey C, Dupuy A, Ferrari P, et al. CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications. MAbs 2016; 8:867-78; PMID:26984268; http://dx.doi.org/10.1080/19420862.2016.1162932
-
(2016)
MAbs
, vol.8
, pp. 867-878
-
-
Steinmetz, A.1
Vallée, F.2
Beil, C.3
Lange, C.4
Baurin, N.5
Beninga, J.6
Capdevila, C.7
Corvey, C.8
Dupuy, A.9
Ferrari, P.10
-
262
-
-
62849095162
-
Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site
-
19299620
-
Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, Man W, Peale F, Ross S, Wiesmann C, et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009; 323:1610-4; PMID:19299620; http://dx.doi.org/10.1126/science.1165480
-
(2009)
Science
, vol.323
, pp. 1610-1614
-
-
Bostrom, J.1
Yu, S.F.2
Kan, D.3
Appleton, B.A.4
Lee, C.V.5
Billeci, K.6
Man, W.7
Peale, F.8
Ross, S.9
Wiesmann, C.10
-
263
-
-
79955545620
-
High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity
-
21526167
-
Bostrom J, Haber L, Koenig P, Kelley RF, Fuh G. High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity. PLoS One 2011; 6:e17887; PMID:21526167; http://dx.doi.org/10.1371/journal.pone.0017887
-
(2011)
PLoS One
, vol.6
, pp. e17887
-
-
Bostrom, J.1
Haber, L.2
Koenig, P.3
Kelley, R.F.4
Fuh, G.5
-
264
-
-
84899748992
-
A two-in-one antibody engineered from a humanized interleukin 4 antibody through mutation in heavy chain complementarity-determining regions
-
24618680
-
Lee CV, Koenig P, Fuh G. A two-in-one antibody engineered from a humanized interleukin 4 antibody through mutation in heavy chain complementarity-determining regions. MAbs 2014; 6:622-7; PMID:24618680; http://dx.doi.org/10.4161/mabs.28483
-
(2014)
MAbs
, vol.6
, pp. 622-627
-
-
Lee, C.V.1
Koenig, P.2
Fuh, G.3
-
265
-
-
84872525097
-
Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation
-
23172311
-
Huang S, Li C, Armstrong EA, Peet CR, Saker J, Amler LC, Sliwkowski MX, Harari PM. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res 2012; 73:824-33; PMID:23172311; http://dx.doi.org/10.1158/0008-5472.CAN-12-1611
-
(2012)
Cancer Res
, vol.73
, pp. 824-833
-
-
Huang, S.1
Li, C.2
Armstrong, E.A.3
Peet, C.R.4
Saker, J.5
Amler, L.C.6
Sliwkowski, M.X.7
Harari, P.M.8
-
266
-
-
84941991989
-
Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors
-
26034219
-
Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messerschmith W, Blumenschein GR, Jr, Tabernero J, Roda D, Calles A, Jimeno A, et al. Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. Clin Cancer Res 2015; 21:2462-70; PMID:26034219; http://dx.doi.org/10.1158/1078-0432.CCR-14-2412
-
(2015)
Clin Cancer Res
, vol.21
, pp. 2462-2470
-
-
Juric, D.1
Dienstmann, R.2
Cervantes, A.3
Hidalgo, M.4
Messerschmith, W.5
Blumenschein, G.R.6
Tabernero, J.7
Roda, D.8
Calles, A.9
Jimeno, A.10
-
268
-
-
77954638589
-
Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties
-
20150180
-
Wozniak-Knopp G, Bartl S, Bauer A, Mostageer M, Woisetschläger M, Antes B, Ettl K, Kainer M, Weberhofer G, Wiederkum S, et al. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains:Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng Des Sel 2010; 23:289-297; PMID:20150180; http://dx.doi.org/10.1093/protein/gzq005
-
(2010)
Protein Eng Des Sel
, vol.23
, pp. 289-297
-
-
Wozniak-Knopp, G.1
Bartl, S.2
Bauer, A.3
Mostageer, M.4
Woisetschläger, M.5
Antes, B.6
Ettl, K.7
Kainer, M.8
Weberhofer, G.9
Wiederkum, S.10
-
269
-
-
84855857695
-
Stabilisation of the Fc fragment of human IgG1 by engineered intradomain disulfide bonds
-
22272277
-
Wozniak-Knopp G, Stadlmann J, Rüker F. Stabilisation of the Fc fragment of human IgG1 by engineered intradomain disulfide bonds. PLoS One 2012; 7:e30083; PMID:22272277; http://dx.doi.org/10.1371/journal.pone.0030083
-
(2012)
PLoS One
, vol.7
, pp. e30083
-
-
Wozniak-Knopp, G.1
Stadlmann, J.2
Rüker, F.3
-
270
-
-
84857263421
-
Directed evolution of stabilized IgG1-Fc scaffolds by application of strong heat shock to libraries displayed on yeast
-
22285845
-
Traxlmayr MW, Faissner M, Stadlmayr G, Hasenhindl C, Antes B, Rüker F, Obinger C. Directed evolution of stabilized IgG1-Fc scaffolds by application of strong heat shock to libraries displayed on yeast. Biochim Biophys Acta 2012; 1824:542-9; PMID:22285845; http://dx.doi.org/10.1016/j.bbapap.2012.01.006
-
(2012)
Biochim Biophys Acta
, vol.1824
, pp. 542-549
-
-
Traxlmayr, M.W.1
Faissner, M.2
Stadlmayr, G.3
Hasenhindl, C.4
Antes, B.5
Rüker, F.6
Obinger, C.7
-
271
-
-
84875681317
-
Directed evolution of Her2/neu-binding IgG1-Fc for improved stability and resistance to aggregation by using yeast surface display
-
23267121
-
Traxlmayr MW, Lobner E, Antes B, Kainer M, Wiederkum S, Hasenhindl C, Stadlmayr G, Rüker F, Woisetschläger M, Moulder K, et al. Directed evolution of Her2/neu-binding IgG1-Fc for improved stability and resistance to aggregation by using yeast surface display. Protein Eng Des Sel 2013; 26:255-65; PMID:23267121; http://dx.doi.org/10.1093/protein/gzs102
-
(2013)
Protein Eng Des Sel
, vol.26
, pp. 255-265
-
-
Traxlmayr, M.W.1
Lobner, E.2
Antes, B.3
Kainer, M.4
Wiederkum, S.5
Hasenhindl, C.6
Stadlmayr, G.7
Rüker, F.8
Woisetschläger, M.9
Moulder, K.10
-
272
-
-
84889822148
-
CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery
-
23995618
-
Fennell BJ, McDonnell B, Tam AS, Chang L, Steven J, Broadbent ID, Gao H, Kieras E, Alley J, Luxenberg D, et al. CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery. MAbs 2013; 5:882-95; PMID:23995618; http://dx.doi.org/10.4161/mabs.26201
-
(2013)
MAbs
, vol.5
, pp. 882-895
-
-
Fennell, B.J.1
McDonnell, B.2
Tam, A.S.3
Chang, L.4
Steven, J.5
Broadbent, I.D.6
Gao, H.7
Kieras, E.8
Alley, J.9
Luxenberg, D.10
-
273
-
-
0031672581
-
Mitogenic properties of a bispecific single-chain Fv-Ig fusion generated from CD2-specific mAb to distinct epitopes
-
9885907
-
Connelly RJ, Hayden MS, Scholler JK, Tsu TT, Dupont B, Ledbetter JA, Kanner SB. Mitogenic properties of a bispecific single-chain Fv-Ig fusion generated from CD2-specific mAb to distinct epitopes. Int Immunol 1998; 10:1863-72; PMID:9885907
-
(1998)
Int Immunol
, vol.10
, pp. 1863-1872
-
-
Connelly, R.J.1
Hayden, M.S.2
Scholler, J.K.3
Tsu, T.T.4
Dupont, B.5
Ledbetter, J.A.6
Kanner, S.B.7
-
274
-
-
84885143903
-
Application of bispecific antibody against antigen and hapten for immunodetection and immunopurification
-
24071736
-
Kim H, Park S, Lee HK, Chung J. Application of bispecific antibody against antigen and hapten for immunodetection and immunopurification. Exp Mol Med 2013; 45:e43; PMID:24071736; http://dx.doi.org/10.1038/emm.2013.83
-
(2013)
Exp Mol Med
, vol.45
, pp. e43
-
-
Kim, H.1
Park, S.2
Lee, H.K.3
Chung, J.4
-
275
-
-
84895077137
-
Bispecific Her2 × cotinine antibody in combination with cotinine-(histidine)2-iodine for the pre-targeting of Her2-positive breast cancer xenografts
-
24292501
-
Yoon S, Kim YH, Kang SH, Kim SK, Lee HK, Kim H, Chung J, Kim IH. Bispecific Her2 × cotinine antibody in combination with cotinine-(histidine)2-iodine for the pre-targeting of Her2-positive breast cancer xenografts. J Cancer Res Clin Oncol 2014; 140:227-33; PMID:24292501; http://dx.doi.org/10.1007/s00432-013-1548-4
-
(2014)
J Cancer Res Clin Oncol
, vol.140
, pp. 227-233
-
-
Yoon, S.1
Kim, Y.H.2
Kang, S.H.3
Kim, S.K.4
Lee, H.K.5
Kim, H.6
Chung, J.7
Kim, I.H.8
-
276
-
-
33750741418
-
Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region
-
16861252
-
Natsume A, Wakitani M, Yamne-Ohnuki N, Shoji-Hosaka E, Niwa R, Uchida K, Satoh M, Shitara K. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region. J Biochem 2006; 140:359-68; PMID:16861252; http://dx.doi.org/10.1093/jb/mvj157
-
(2006)
J Biochem
, vol.140
, pp. 359-368
-
-
Natsume, A.1
Wakitani, M.2
Yamne-Ohnuki, N.3
Shoji-Hosaka, E.4
Niwa, R.5
Uchida, K.6
Satoh, M.7
Shitara, K.8
-
277
-
-
84954522654
-
Bispecific Antibody Conjugated Manganese-Based Magnetic Engineered Iron Oxide for Imaging of HER2/neu- and EGFR-Expressing Tumors
-
26722378
-
Wu SC, Chen YJ, Wang HC, Chou MY, Chang TY, Yuan SS, Chen CY, Hou MF, Hsu JT, Wang YM. Bispecific Antibody Conjugated Manganese-Based Magnetic Engineered Iron Oxide for Imaging of HER2/neu- and EGFR-Expressing Tumors. Theranostics 2016; 6:118-30; PMID:26722378; http://dx.doi.org/10.7150/thno.13069
-
(2016)
Theranostics
, vol.6
, pp. 118-130
-
-
Wu, S.C.1
Chen, Y.J.2
Wang, H.C.3
Chou, M.Y.4
Chang, T.Y.5
Yuan, S.S.6
Chen, C.Y.7
Hou, M.F.8
Hsu, J.T.9
Wang, Y.M.10
-
278
-
-
84973488464
-
Melanoma-Directed Activation of Apoptosis Using a Bispecific Antibody Directed at MCSP and TRAIL Receptor-2/Death Receptor-5
-
26967487
-
He Y, Hendriks D, van Ginkel R, Samplonius D, Bremer E, Helfrich W. Melanoma-Directed Activation of Apoptosis Using a Bispecific Antibody Directed at MCSP and TRAIL Receptor-2/Death Receptor-5. J Invest Dermatol 2016; 136:541-4; PMID:26967487; http://dx.doi.org/10.1016/j.jid.2015.11.009
-
(2016)
J Invest Dermatol
, vol.136
, pp. 541-544
-
-
He, Y.1
Hendriks, D.2
van Ginkel, R.3
Samplonius, D.4
Bremer, E.5
Helfrich, W.6
-
279
-
-
84910673427
-
A multifunctional bispecific antibody protects against Pseudomonas aeruginosa
-
25391481
-
DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, Bonnell J, Fleming R, Bezabeh B, Dimasi N, et al. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med 2014; 6:262ra155; PMID:25391481; http://dx.doi.org/10.1126/scitranslmed.3009655
-
(2014)
Sci Transl Med
, vol.6
, pp. 262ra155
-
-
DiGiandomenico, A.1
Keller, A.E.2
Gao, C.3
Rainey, G.J.4
Warrener, P.5
Camara, M.M.6
Bonnell, J.7
Fleming, R.8
Bezabeh, B.9
Dimasi, N.10
-
280
-
-
85010871699
-
The SAATELLITE and EVADE clinical studies within the COMBACTE Consortium: A public-private collaborative effort in designing and performing clinical trials for novel antibacterial drugs to prevent nosocomial pneumonia
-
François B, Chastre J, Eggiman P, Laterre PF, Torres A, Sanchez M, Esser MT, Bishop B, Bonten M, Goosens H, Jafri HS. The SAATELLITE and EVADE clinical studies within the COMBACTE Consortium:A public-private collaborative effort in designing and performing clinical trials for novel antibacterial drugs to prevent nosocomial pneumonia. Clin Infect Dis 2016; 63 Suppl 2:S46-51. doi:10.1093/cid/ciw245
-
(2016)
Clin Infect Dis
, vol.63
, pp. S46-S51
-
-
François, B.1
Chastre, J.2
Eggiman, P.3
Laterre, P.F.4
Torres, A.5
Sanchez, M.6
Esser, M.T.7
Bishop, B.8
Bonten, M.9
Goosens, H.10
Jafri, H.S.11
-
281
-
-
0142061073
-
Di-diabody: a novel tetravalent bispecific antibody molecule by design
-
12969563
-
Lu D, Jimenez X, Zhang H, Atkins A, Brennan L, Balderes P, Bohlen P, Witte L, Zhu Z. Di-diabody:a novel tetravalent bispecific antibody molecule by design. J Immunol Methods 2003; 279:219-32; PMID:12969563
-
(2003)
J Immunol Methods
, vol.279
, pp. 219-232
-
-
Lu, D.1
Jimenez, X.2
Zhang, H.3
Atkins, A.4
Brennan, L.5
Balderes, P.6
Bohlen, P.7
Witte, L.8
Zhu, Z.9
-
282
-
-
21244441508
-
A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity
-
15757893
-
Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, Corcoran E, Mangalampalli V, Bassi R, Anselma D, et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 2005; 280:19665-72; PMID:15757893; http://dx.doi.org/10.1074/jbc.M500815200
-
(2005)
J Biol Chem
, vol.280
, pp. 19665-19672
-
-
Lu, D.1
Zhang, H.2
Koo, H.3
Tonra, J.4
Balderes, P.5
Prewett, M.6
Corcoran, E.7
Mangalampalli, V.8
Bassi, R.9
Anselma, D.10
-
283
-
-
0344654890
-
Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region
-
10413102
-
Alt M, Müller R, Kontermann RE. Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region. FEBS Lett 1999; 454:90-4; PMID:10413102
-
(1999)
FEBS Lett
, vol.454
, pp. 90-94
-
-
Alt, M.1
Müller, R.2
Kontermann, R.E.3
-
284
-
-
84964502118
-
Pharmacokinetic properties of IgG and various Fc fusion proteins in mice
-
26514880
-
Unverdorben F, Richter F, Hutt M, Seifert O, Malinge P, Fischer N, Kontermann RE. Pharmacokinetic properties of IgG and various Fc fusion proteins in mice. MAbs 2016; 8:120-8; PMID:26514880; http://dx.doi.org/10.1080/19420862.2015.1113360
-
(2016)
MAbs
, vol.8
, pp. 120-128
-
-
Unverdorben, F.1
Richter, F.2
Hutt, M.3
Seifert, O.4
Malinge, P.5
Fischer, N.6
Kontermann, R.E.7
-
285
-
-
84884522728
-
Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody
-
24086580
-
Wang L, He Y, Zhang G, Ma J, Liu C, He W, Wang W, Han H, Boruah BM, Gao B. Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody. PLoS One 2013; 8:e75589. PMID:24086580; http://dx.doi.org/10.1371/journal.pone.0075589
-
(2013)
PLoS One
, vol.8
, pp. e75589
-
-
Wang, L.1
He, Y.2
Zhang, G.3
Ma, J.4
Liu, C.5
He, W.6
Wang, W.7
Han, H.8
Boruah, B.M.9
Gao, B.10
-
286
-
-
84867000911
-
The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificity
-
22988132
-
Seifert O, Plappert A, Heidel N, Fellermeier S, Messerschmidt SK, Richter F, Kontermann RE. The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificity. Protein Eng Des Sel 2012; 25:603-12; PMID:22988132; http://dx.doi.org/10.1093/protein/gzs059
-
(2012)
Protein Eng Des Sel
, vol.25
, pp. 603-612
-
-
Seifert, O.1
Plappert, A.2
Heidel, N.3
Fellermeier, S.4
Messerschmidt, S.K.5
Richter, F.6
Kontermann, R.E.7
-
287
-
-
84964316543
-
Editorial overview: special section: New concepts in antibody therapeutics: What's in store for antibody therapy
-
27083411
-
Schuurman J, Parren PW. Editorial overview:special section:New concepts in antibody therapeutics:What's in store for antibody therapy. Curr Opin Immunol 2016; 40:VII-XIII; PMID:27083411; http://dx.doi.org/10.1016/j.coi.2016.04.001
-
(2016)
Curr Opin Immunol
, vol.40
, pp. VII-XIII
-
-
Schuurman, J.1
Parren, P.W.2
-
288
-
-
84856120429
-
Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?
-
22248267
-
Deng R, Jin F, Prabhu S, Iyer S. Monoclonal antibodies:what are the pharmacokinetic and pharmacodynamic considerations for drug development? Expert Opin Drug Metab Toxicol 2012; 8:141-60; PMID:22248267; http://dx.doi.org/10.1517/17425255.2012.643868
-
(2012)
Expert Opin Drug Metab Toxicol
, vol.8
, pp. 141-160
-
-
Deng, R.1
Jin, F.2
Prabhu, S.3
Iyer, S.4
-
289
-
-
84940955731
-
The neonatal Fc receptor, FcRn, as a target for drug delivry and therapy
-
25703189
-
Sockolosky JT, Szoka FC. The neonatal Fc receptor, FcRn, as a target for drug delivry and therapy. Adv Drug Deliv Rev 2015; 91:109-24; PMID:25703189; http://dx.doi.org/10.1016/j.addr.2015.02.005
-
(2015)
Adv Drug Deliv Rev
, vol.91
, pp. 109-124
-
-
Sockolosky, J.T.1
Szoka, F.C.2
-
290
-
-
84929179769
-
Developability assessment during the selection of novel therpaeutic antibodies
-
25821140
-
Jarasch A, Koll H, Regula JT, Bader M, Papadimitriou A, Kettenberger H. Developability assessment during the selection of novel therpaeutic antibodies. J Pharm Sci 2015; 104:1885-98; PMID:25821140; http://dx.doi.org/10.1002/jps.24430
-
(2015)
J Pharm Sci
, vol.104
, pp. 1885-1898
-
-
Jarasch, A.1
Koll, H.2
Regula, J.T.3
Bader, M.4
Papadimitriou, A.5
Kettenberger, H.6
-
291
-
-
84925761458
-
Accelerated formulation development of monoclonal antibodies (mAbs) an mAb-based modalities: a review of methods and tools
-
25576149
-
Razinkov VI, Treuheit MJ, Becker GW. Accelerated formulation development of monoclonal antibodies (mAbs) an mAb-based modalities:a review of methods and tools. J Biomol Screen 2015; 20:468-83; PMID:25576149; http://dx.doi.org/10.1177/1087057114565593
-
(2015)
J Biomol Screen
, vol.20
, pp. 468-483
-
-
Razinkov, V.I.1
Treuheit, M.J.2
Becker, G.W.3
-
292
-
-
84976293596
-
Drug development of therapeutic monoclonal antibodies
-
27342605
-
Mould DR, Meibohm B. Drug development of therapeutic monoclonal antibodies. BioDrugs 2016; 30:275-93; PMID:27342605; http://dx.doi.org/10.1007/s40259-016-0181-6
-
(2016)
BioDrugs
, vol.30
, pp. 275-293
-
-
Mould, D.R.1
Meibohm, B.2
-
293
-
-
84991036052
-
Oxidation in the complementarity-determining regions differentially influences the properties of therapeutic antibodies
-
27612038
-
Dashivets T, Stracke J, Dengl S, Knaupp A, Pollmann J, Buchner J, Schlothauer T. Oxidation in the complementarity-determining regions differentially influences the properties of therapeutic antibodies. MAbs 2016; PMID:27612038
-
(2016)
MAbs
-
-
Dashivets, T.1
Stracke, J.2
Dengl, S.3
Knaupp, A.4
Pollmann, J.5
Buchner, J.6
Schlothauer, T.7
-
294
-
-
84995790815
-
Determination of critical quality attributes for monoclonal antibodies using quality by design principles
-
Alt N, Zhang TY, Motchnik P, Taticek R, Quarmby V, Schlothauer T, Beck H, Emrich T, Harris RJ. Determination of critical quality attributes for monoclonal antibodies using quality by design principles. Biologicals 2016; 44:291-305; http://dx.doi.org/10.1016/j.biologicals.2016.06.005
-
(2016)
Biologicals
, vol.44
, pp. 291-305
-
-
Alt, N.1
Zhang, T.Y.2
Motchnik, P.3
Taticek, R.4
Quarmby, V.5
Schlothauer, T.6
Beck, H.7
Emrich, T.8
Harris, R.J.9
-
295
-
-
84953382225
-
Functional assessment of antibody oxidation by native mass spectrometry
-
26000623
-
Haberger M, Heidenreich AK, Schlothauer T, Hook M, Gassner J, Bomans K, Yegres M, Zwick A, Zimmermann B, Wegele H, et al. Functional assessment of antibody oxidation by native mass spectrometry. MAbs 2015; 7:891-900; PMID:26000623; http://dx.doi.org/10.1080/19420862.2015.1052199
-
(2015)
MAbs
, vol.7
, pp. 891-900
-
-
Haberger, M.1
Heidenreich, A.K.2
Schlothauer, T.3
Hook, M.4
Gassner, J.5
Bomans, K.6
Yegres, M.7
Zwick, A.8
Zimmermann, B.9
Wegele, H.10
-
296
-
-
84896514767
-
Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: Susceptibility vs. functionality of critical quality attributes
-
2444108
-
Haberger M, Bomans K, Diepold K, Hook M, Gassner J, Schlothauer T, Zwick A, Spick C, Kepert JF, Hienz B, et al. Assessment of chemical modifications of sites in the CDRs of recombinant antibodies:Susceptibility vs. functionality of critical quality attributes. MAbs 2014; 6:327-39; PMID:2444108; http://dx.doi.org/10.4161/mabs.27876
-
(2014)
MAbs
, vol.6
, pp. 327-339
-
-
Haberger, M.1
Bomans, K.2
Diepold, K.3
Hook, M.4
Gassner, J.5
Schlothauer, T.6
Zwick, A.7
Spick, C.8
Kepert, J.F.9
Hienz, B.10
-
297
-
-
84959020772
-
Conformational destabilization of immunoglobulin G increases the low pH binding affinity with the neonatal Fc receptor
-
26627822
-
Walters BT, Jensen PF, Larraillet V, Lin K, Patapoff T, Schlothauer T, Rand KD, Zhang J. Conformational destabilization of immunoglobulin G increases the low pH binding affinity with the neonatal Fc receptor. J Biol Chem 2016; 291:1817-25; PMID:26627822; http://dx.doi.org/10.1074/jbc.M115.691568
-
(2016)
J Biol Chem
, vol.291
, pp. 1817-1825
-
-
Walters, B.T.1
Jensen, P.F.2
Larraillet, V.3
Lin, K.4
Patapoff, T.5
Schlothauer, T.6
Rand, K.D.7
Zhang, J.8
|